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MS'MACT 
Reactive oxygen species (ROS) are implicated in the inflammatory, autoimmune, 
connective tissue disease, systemic lupus er)1:hematosus (SLE), particularly in respect of 
processes leading to the formation of pathogenic anti-DNA antibodies. Exposure to ROS 
increases the antigenicity of DNA. These reactive species are generally produced by 
ionizing radiation, redox-cycling drugs and many carcinogenic chemicals and can cause 
DNA damage, including single strand breaks and base modifications. Among these 
radicals, superoxide anion radical and singlet oxygen species are the most abundant. 
Superoxide is generated in vivo by several enzymatic and non-enzymatic pathways in 
mammalian tissues. Singlet oxygen is not a direct product of the enzymatic reactions, but 
rather a secondary reaction product and is a potent biological toxin. Both have been 
implicated in several disease states via alteration of biomolecules. Oxidative damage to 
cellular DNA can lead to mutations imd may, therefore, play an important role in 
carcinogenesis and other biological processes. 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
involving both humoral and cellular aspects of the innate and acquired immune systems. 
Lupus is characterized by autoantibodies with a spectrum of specificities that participate 
in disease pathogenesis. In SLE, antibodies to DNA occur prominently and serve as 
markers of diagnostic and prognostic significance. The antibodies are predominantly IgG 
class and bind to conserved sites on the backbone of both single stranded (ss) as well as 
double-stranded (ds) DNA. Studies have emphasised that this disease is a complex 
genetic trait with contributions from major histocompatibility complex (MHC) genes and 
multiple non-MHC genes. The apoptosis genes Fas and Fas ligand (Fas L) are candidate 
contributory gene in human SLE, as mutations of these genes result in autoimmunity in 
several murine models of this disease. 
In the present study, commercially available calf thymus DNA was purified and 
fragmented by using micrococcal nuclease and 200 bp fragments were selected for 
further studies. DNA was modified by singlet oxygen and superoxide anion radicals 
generated by riboflavin on exposure to UV light. The results indicated single strand 
breaks and base modifications. The induced modifications in DNA were analyzed by UV 
and fluorescence spectroscopic techniques. The modified DNA showed hyperchromicity 
at 260 nm, as compared to native DNA, thereby, reflecting the change in DNA helix 
organisation. The Tm of O2-O2 -DNA was found to be 78°C, whereas, native DNA 
showed a Tm of 86°C. A net decrease of 8°C in the Tm value of '02-02~-DNA indicates 
a partial destruction of its secondary structure. The single strand breaks, induced in DNA 
as a result of modification, were detected by nuclease SI digestibility assay. The 
modified DNA fragments were employed in competitive assays to delineate the epitope 
recognition of induced antibodies against 02-02~ -DNA. 
The antigenicity of O2-O2 -DNA was probed by inducing antibodies in rabbits. 
The repertoire of specificities of induced antibodies were evaluated by direct binding and 
competition ELISA. The induced antibodies exhibited polyspecificity, a property 
commonly associated with SLE anti-DNA autoantibodies. Anti-'02-02~ -DNA antibodies 
showed preferential binding to ROS-DNA. 
Twenty four SLE sera were studied for their binding to native and 'O2-O2"" -DNA. 
Specificity of antigen binding was assessed by inhibition ELISA. In direct binding assay, 
all SLE autoantibodies bound '02-02~ -DNA in preference to dsDNA. The preference 
was reiterated by inhibition ELISA. The binding specificity of native and O2-O2 -DNA 
with SLE anti-DNA autoantibodies was also confirmed by gel retardation assay. 
Similarly, cancer sera were screened for the presence of antibodies reactive with 
native and '02-02~-DNA. The study consisted of 34 sera from patients with various types 
of malignancies. Direct binding ELISA showed greater recognition for '02-02~ -DNA as 
compared to native form. Four sera from breast cancer showed higher recognition of 'O2-
02~ -DNA than native DNA. Five sera from cancer of urinary bladder showed higher 
reactivity with 'O2-O2" -DNA. Four sera from cancer of gall bladder also showed higher 
recognition with 'O2-O2" -DNA. Three sera from prostrate cancer showed moderate 
recognition with '02-02~ -DNA, while only one sera showed almost equal inhibition with 
both native and '02-02~ -DNA. All the sera of lung cancer, having a history of smoking 
showed higher recognition of '02-02~ -DNA. Among four sera from oral cancer, two 
showed higher recognition of '02-02~ -DNA, one showed moderate recognition, while 
one sera showed higher recognition of nDNA as compared to '02-02~ -DNA. Four sera 
from cancer of head and neck, two from vulva, one serum each from CML and 
Ill 
Hodgkin's lymphoma showed higher recognition for '02-02~ -DNA as compared to 
nDNA. The results indicate that ROS appears to enhance the antigenicity of native DNA, 
suggesting role of ROS damaged DNA in the production of autoantibodies in cancer 
patients. 
The role of ROS in the development of cancer was further supported by detection 
of oxidative lesions in DNA isolated from lymphocytes of various cancer patients, using 
anti-'02-02 -DNA IgG as probe. DNA from two patients with lung cancer recognized 
anti-'02-0'2~ -DNA IgG appreciably and inhibited its activity to 64% and 68%. DNA 
from patients with oral and prostrate carcinoma too inhibited antibody activity 
appreciably. 
In conclusion, singlet oxygen and superoxide anion radical causes damage to 
DNA and renders it highly immunogenic. Antibodies against 'O2-O2 -DNA are 
polyspecific in nature resembling the antigen binding characteristics of SLE anti-DNA 
autoantibodies. It is postulated that 'O2-O2 -DNA may play a major role in the production 
of SLE anti-DNA autoantibodies by the modification of DNA (or nucleosomes) thus 
forming neoantigen(s) resulting in production of autoantibodies. Further the anti-'02-02~ 
-DNA IgG raised in experimental animal was able to detect oxidative lesions in DNA of 
cancer patients. 
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In 1953, James Watson and Francis Crick first enunciated the double helical 
structure of DNA with the axis of the helix running perpendicular to the nitrogenous 
bases. This model of DNA, known as B-DNA, is the most widely accepted structure of 
DNA in solution. However, DNA can adopt many more different conformations or 
structures (Rich, 1984). The major physical evidence for the structure of DNA comes 
from X-ray diffraction studies of fibres (Langridge et al, 1960). The differences in 
molecular forms are of crucial importance in understanding the manner in which proteins 
interact and recognize nucleotide sequences in B-DNA. Wang et al. (1979) described a 
variant of B-DNA double helix in a DNA hexamer with a sequence of (CGCGCG). The 
two strands of the duplex were antiparallel and connected by Watson-Crick base pairs, 
but the helix was left-handed. The backbone had a zig-zag shape and was termed as 
Z-DNA. The Z- conformation is adopted by flipping of the base pairs upside down. 
Triple stranded nucleic acid have also been found to exist in DNA. A typical example is 
the formation of triple stranded DNA as an intermediate in the action of E.Coli 
recombination enzyme Rec A (Camerine-Otero and Hseih, 1993). The X-ray diffraction 
pattern of polynucleotides such as polyinosinic and polyguanylic acid indicate that the 
strands are parallel to each other with a three or four fold symmetry axis along the fibre 
(Rich, 1958; Zimmerman et al, 1975). Other conformation includes the cruciform 
structure, widely found in the eukaryotic genome (Wilson and Thomas, 1974; Lu et al.. 
1992) and quadruple-stranded nucleic acids (Rich, 1958). 
Antigenicity of DNA 
The antigenicity of nucleic acids has received considerable attention, since the 
first report of anti-DNA antibodies in sera of patients with systemic lupus erythematosus 
(SLE) in 1957 and identification of DNA as the reactant of these antibodies (Cepelline et 
al., 1957). In the early 1960's, methods were developed for the experimental induction of 
anfibodies to nucleic acids (Levine et al., 1960; Erlanger and Beiser 1964; Plescia et al.. 
1964). Immunizafion of experimental animals with denatured DNA, synthefic nucleic 
acid polymers like poly(dT), poly(dC), poly(dA), poly(dl), poly(G), double stranded 
RNA, left handed Z-DNA and double stranded DNA with the notable exception of native 
B-DNA can induce antibodies that react selectively with the immunogen (Stollar, 1986). 
The DNA molecule has several unique features, which have a direct bearing on its 
immune reactions. In nature it exists in different conformational forms including both 
right handed (A- and B-DNA) and left handed helix (Z-DNA) (Setlow, 1992). DNA is 
a multi determinant polymer and its polyanionic nature results in a hydrophobic core of 
stacked bases and a sugar phosphate polyanionic backbone. The phosphate residues make 
DNA a notoriously sticky antigen. 
While native B-DNA is non-immunogenic, the left-handed Z-DNA is a potent 
immunogen (Lafer et al, 1981; Madaio, 1984) and induces selective and specific 
antibodies (Zarling et al, 1984). Those DNA structures that differ significantly from 
B-DNA are much stronger immunologic stimuli than nDNA (Anderson et al, 1988a). 
Purified calf thymus DNA modified with drugs, hormones, fi-ee radicals etc. has been 
reported to induce antibodies against the modified DNA (Alam and Ali et al, 1992; Arif 
et al, 1994; Moinuddin and Ali, 1994; Arjumand et al, 1995; Ara and Ali, 1995). 
Polynucleotides that differ from B-conformation are much stronger immunogens (Braun 
and Lee; 1988), while polynucleotides of B-conformation become immunogenic after 
modification with furocoumarins (Arif and Ali, 1996). 
The reversal in handedness of double stranded helical DNA accompanying B to 
Z-transition is one of the most dramatic examples of DNA polymorphism (Pietrasanta et 
al, 1994). A-Iike DNA is characterized by more base pairs per turn of the helix and a 
wider minor groove than B-like DNA. A-like DNA is not associated with the living 
system and is generally formed under conditions of low water content (Saenger, 1984). It 
has been found out that DNA in some Bacillus species is induced in A-like conformation 
(Setlow, 1992). 
Mammalian DNA elicit poor immune response to single stranded DNA and fails 
to induce antibodies against native or double stranded DNA, the serologic marker of SLE 
(Madaio et al, 1984). However, studies have shown that DNA complexes with synthetic 
peptide Fus-I can induce anti-dsDNA response in mice (Desai et al, 1993). This led to 
the conclusion that antigen drive in lupus involves either a substance other than DNA or 
DNA in a form (e.g. nucleosomes) that is not readily mimicked by artificial complexes 
(Burlingame et al, 1993, Mohan et ai, 1993). Since the antibody reactivity of both single 
and double stranded forms appears independent of DNA species origin, these findings 
suggest recognition of conserved conformational determinants (e.g. helical backbone of 
B-DNA) and a lack of DNA sequences microheterogeneity on antigenicity (StoUar, 1975; 
Pisetsky, 1993). Anti-DNA antibodies may also result by autoimmunization with 
chromatin, rather than native DNA (Theofilopoulos, 1995). 
Immunization of animals with nucleic acid-MBSA complexes resulted in 
antibodies that reacted with fi"ee denatured DNA, but not with B-conformation of DNA. 
They also showed cross-reactivity with denatured DNA from widely different species. 
There is compelling evidence that bacterial DNA, in contrast to mammalian DNA, 
induces a variety of responses in both nonnal humans and animals (Pisetsky, 1996). 
Antibodies to bacterial DNA in normal human sera are predominantly of IgG2 subclass, 
whereas, lupus anti-DNA antibodies are mainly IgGl and IgG3. Animals following 
immunization with bacterial DNA induce antibodies showing negligible cross-reactivity 
with mammalian DNA (Gilkeson et al, 1991). Low molecular weight DNA was found in 
the DNA-anti DNA complexes of lupus patients and is enriched in CG contents (Sano et 
al, 1983). The CG rich DNA region has the tendency to form Z-DNA, which is highly 
immunogenic. 
The immunologic potential of DNA has immediate relevance in the therapeutic 
arena. DNA vaccine seems to be a broadly applicable technique for generating protective 
immune response against viral, parasitic and tumour antigens in animal ranging from 
mice to non-human primates. DNA vaccine research is providing new insights into some 
of the basic immunological mechanisms of vaccination such as antigen presentation, the 
role of effector cells and immunoregulatory factors. In addition, DNA vaccines help to 
manipulate the immune system in situations where the response to agents is inappropriate 
or ineffective. The study of the potential deleterious effect of DNA vaccines leads to 
further knowledge regarding the relationship between bacterial DNA and the immune 
system, as well as its potential application for the study of neonatal tolerance and 
autoimmunity (Mor and Eliza, 2001). 
Free radicals 
A free radical may be defined as any chemical species that contains one or more 
unpaired electrons and is capable of independent existence. They are extremely reactive, 
hence their half lives are very short and steady state concentrations quite low (Freeman, 
1984; Halliwell and Gutteridge, 1984; 1989; Cadenas, 1989). They can be formed by 
hemolytic cleavage, heterolytic cleavage or by the loss of single electron from a 
molecule. As such, free radicals can be formed in three ways: 
(i) By the homolytic cleavage of a covalent bond of a molecule, with each fragment 
having an unpaired electron (Von Sonntag, 1987). 
(ii) By the loss of a single electron from a molecule, 
(iii) By the addition of a single electron to a molecule. 
The latter, electron transfer, is more common process in biological systems than 
homolytic fission, which generally requires high energy input from either high 
temperatures, UV light or ionising radiations. Free radicals can be positively charged, 
negatively charged or electrically neutral. The most important free radicals in biological 
systems are radical derivatives of oxygen known as reactive oxygen species (ROS), ROS 
not only includes oxygen-centered radicals such as superoxide anion (O2 ) and hydroxy! 
radical (OH), but also non-radical derivatives of oxygen, such as hydrogen peroxide 
(H2O2), singlet oxygen ('O2), hypochlorous acid (HOCl) and ozone (O3). The reactivity 
of ROS is due to the unstable electronic configuration of these radicals. 
In living cells, ROS are produced continuously during normal aerobic metabolism 
(Halliwell and Aruoma, 1991) as well as in many pathologic conditions such as tissue 
ischaemia, cancer, inflammation and degenerative diseases (Halliwell and Gutteridge, 
1984; Vuilaume, 1987). The autooxidation of certain small cytoplasmic molecules such 
as catecholamine, flavins and the activity of some enzymes (xanthine oxidase and 
aldehyde dehydrogenase) have been kno>Mi to produce ROS, in vivo (Fridovich, 1983). 
Besides these, the metabolism of arachidonic acid and respiratory burst from phagocytes 
also give rise to ROS (Halliwell and Gutteridge, 1989). 
It has been demonstrated that iron, in presence of H2O2 and ascorbate generates 
'OH which causes cleavage of proximate DNA. Besides these endogenous sources, ROS 
are also generated by a number of exogenous sources such as inhaled smoke, polluted air, 
certain ingested food and a variety of other carcinogens. The low wavelength ionising 
radiation (e.g. y and X-ray) and ultraviolet (UV) light are also important exogenous 
sources of ROS (Davies, 1987; Epe, 1991). Hydroxy! radical is also known to be 
generated by UV (254 nm) irradiation of H2O2 (Ara and Mi, 1992; 1993). 
Superoxide anion (O2") is formed by the single electron transfer to ground state 
dioxygen. During mitochondrial respiration 1-5% of oxygen is converted to O2" 
(Freeman and Crapo, 1982; Cross et al, 1987). Superoxide radical shows limited 
reactivity, but in aqueous solution it reacts with itself producing hydrogen peroxide and 
molecular oxygen in presence of enzyme superoxide dismutase (Halliwell, 1994). The 
protonated form of 02~, called perhydroxyl radical (HO2), is more reactive than O2' itself 
(Halliwell and Gutteridge, 1989). 
Molecular oxygen in electronic singlet state is a powerful oxidant. Only one type 
of living cell, the human eosinophil, produces detectable quantities of singlet oxygen 
(Kanofsky et al, 1988). Superoxide radical interacts with (H2O2) to generate 'O2 
molecule which is also generated predominantly in photosensitization reactions. It shows 
high reactivity towards biomolecules. Recently it has been shown that UV-irradiation of 
certain antibiotics (Nalidixic acid, amphotericin-B, cephradine, cefazolin, nafcillin etc.) 
leads to the generation of singlet oxygen (Pandey et al., 2002). 
Much of the toxicity of free radicals in vivo is thought to result from reaction of 
'OH, which can be produced in cells by metal ion dependent conversion of superoxide 
(02~) and hydrogen peroxide or by interaction of ionizing radiation with cellular water 
(von Sonntag, 1987). Hemolytic fission of 0-0 bond in hydrogen peroxide by heat or 
ionizing radiation produces two 'OH radicals. A simple mixture of H2O2 and iron (II) salt 
also forms 'OH as was first observed by Fenton in 1894 
Fe^^ + H2O2 > Fe^^ + OH" + 'OH 
and the second, by the interaction of superoxide anion with H2O2 through the Haber-
Weiss reaction (Haber and Weiss, 1934). 
TABLE - 1 
Some characteristics of reactive oxygen derivatives 
Species 
Super-oxide 
anion 
Singlet 
oxygen 
Hydroxy] 
radical 
Hydrogen 
peroxide 
Chemical symbol 
O2" 
'O2 
*0H 
H2O2 
Origin 
02 + e" 
^02, 
peroxidation 
H2O2, H2O 
0*2~ bio-
generation 
Properties 
Good reductant, 
poor oxidant 
Powerful 
oxidizing agent 
Extremely 
reactive, very 
low diffusion 
distance 
Oxidant, high 
diffusion 
capability 
Protectors 
SOD 
Vit. C, Vit. E. 
P-carotene 
Antioxidants 
Catalase, 
glutathione 
peroxidase 
Adapted from Simic etal. (1989) and Yu (1994). 
0*2 +H2O2 >02 + H20 + *OH 
Hydrogen peroxide though not a free radical, is harmful to the cell because of its 
ability to cross biological membranes and produce the highly reactive hydroxyl radical 
("OH) (Ward et al, 1987; Pryor and Church, 1991). Superoxide and H2O2 though less 
reactive than 'OH have a longer half-life and react with molecules far away from their 
site of production (Halliwell and Gutteridge, 1984; Pryor, 1986). 
Oxidative DNA damage and repair 
Oxidative DNA damage is produced when reactive oxygen species are generated 
in cells by normal aerobic metabolism or by exogenous source such as ionising radiation 
or carcinogenic compounds, which may be implicated in mutagenesis, carcinogenesis and 
aging (Halliwell and Gutteridge, 1990). The endogenous reactions that are likely to 
contribute to ongoing DNA damage are oxidation, methylation, depurination and 
deamination (Totter et al, 1980). Conversion of guanine to 8-hydroxyguanine (8-OHG), 
a frequent product of ROS attack has been found to alter the enzyme-catalyzed 
methylation of adjacent cytosines (Weitzman, 1994), thus providing a link between 
oxidative DNA damage and altered methylation patterns. 
The chemistry of DNA damage by several ROS has been well characterized in 
vitro (von Sonntag, 1987). Different ROS affect DNA in different ways, e.g. H2O2 do not 
react at all with DNA bases. Hydroxyl radical generates a multiplicity of products from 
all four DNA bases and this pattern appeairs to be a diagnostic fingerprint of'OH attack. 
By contrast 'O2 selectively attacks guanine (Van den Akker et al, 1994). The most 
commonly produced base lesion, and the one most often measured as an index of 
oxidative DNA damage, is 8-OHG. It is sometimes measured as the nucleoside 
8-hydroxydeoxyguanosine (8-OHdG) (Ames, 1989). Superoxide is capable of inducing 
strand breaks (Sah et al, 1995). 
Reduction of DNA can also lead to the ring opening product 2,6-diamino-4-
hydroxy-5-formamidopyrimidine (Dizdaroglu, 1991). Other abimdant oxidatively 
modified purine and pyrimidines include 7,8-dihydro-8-oxoadenine (8-oxo-dA), 
2-hydroxyademne, Fapyadenine, 5-hydroxymethyluracil, 5-hydroxycytosine, cytosine 
glycol and thymine glycol. In addition, a large number of other modification of bases and 
sugars have been identified (Dizdaroglu, 1991; 1994; Kamiya et al, 1995). 
Mitochondrial DNA (mtDNA) has been found to be especially vulnerable to 
attack by oxygen free radical (Driggers et al, 1996). Oxidative damage to cellular DNA 
can be mutagenic and may, therefore, play an important role in tumorigenesis. It has been 
shown that 8-OHdG is mutagenic, causing GC-»AT base pair substitutions (Kuchino el 
al, 1987) and can result in activation of the human C-Ha-ras-Igene (oncogene) (Kamiya 
etal, 1992). 
DNA repair is an immediate response after damage and several repair pathways 
are likely to be elicited when cells are exposed to oxygen species (Sage, 1993). The 
nucleotide excision repair system of E.Coli Uvr ABC, however, is not pivotal for 
handling oxidative damage in contrast to its crucial role in the repair of structurally 
distorting lesions, such as pyrimidine photodimers and some carcinogenic adducts 
(Sancer and Tang, 1993). Unrepaired DNA or inaccurate repair of damage can lead to 
cell death (Jackson, 1996). 
In vivo oxidative DNA damage repaired continuously by a variety of enzymes. 
Strand breaks are annealed and modified bases are excised as such or as nucleotides 
(Ramotar and Demple, 1993; Demple and Harrison, 1994). DNA glycosylases excise 
bases and subsequently phosphodiester bonds on each side of the basic site are incised by 
endonucleases allowing the insertion of an intact nucleotide. The formamidopyrimidine-
DNA glycosylase enzyme (Fpg; mut M) in E.Coli repairs the oxidized purines 
8-oxoguanine and 2,6-diamino-4-hydroxy-5-formamidopyrimidine and to lesser extent 
the corresponding adenine derivatives of base excision (Boiteux et al, 1992). The 
formamidopyrimidine DNA glycosylase protein appear to repair 8-oxodG in non coding 
and actively transcribed mammalian DNA sequences with equal efficiency (Bohr et al, 
1995). 
Superoxide anion radical 
One electron reduction of oxygen leads to the formation of superoxide anion 
radical (Florence, 1990; Harris, 1992). The superoxide anion radical (02")is considered 
to be a highly toxic entity in many biological systems (Oberly, 1982; Rotelio, 1986; von 
Sonntag, 1987; Harman, 1993). It is formed in nonnal metabolism as well as through the 
action of many drugs, poisons and radiation. It is also involved in radiation damage, 
DNA damage, phagocytosis, ageing, cancer etc. Since, superoxide dismutase (SOD) is 
specific for 02~ as substrate, it follows that it must be a toxic species. Superoxide 
dismutases (SODs) are metalloenzymes that catalyse very efficiently the dismutation of 
superoxide ions into oxygen and hydrogen peroxide. It has been widely recognized that 
these enzymes, which are present in almost all living organisms provide a defence system 
that is essential for their survival under aerobic conditions. The deleterious role of 
superoxide during ischaemia (McCord, 1988), which occurs in organ transplantation and 
many surgical interventions and during h&art and brain events, suggests that SOD may 
have a potential clinical use. 
Superoxide anion is generated most frequently by the xanthine-xanthine oxidase 
system (Greenwald, 1985). Xanthine oxidase produces O2 when it oxidizes aerobically 
xanthine to urate. The exogenous chemical sources of O2 that can conveniently be used 
to assess the genotoxic potential of oxygen metabolite include: 
(i) Xanthine oxidase acting aerobically on xanthine or hypoxanthine, which produces a 
steady flux of superoxide radical, 
(ii) Potassium superoxide (KO2), which dissolves in water with the liberation of 
superoxide anion radical. 
Superoxide anion is the only species generated by these two systems. However, H2O2 is 
also immediately formed by spontaneous or catalyzed dismutation of O2". Both 
exogenous sources of O2 have been shown to be genotoxic, which is attributed to its 
ability to damage chromosomal DNA (Emrit et al., 1982). Interestingly, chromosomal 
breakage is observed in several autoimmune diseases such as lupus erythematosus, 
rheumatoid arthritis and ulcerative colitis (Emerit, 1986). Therefore, it is possible that 
superoxide radical produced in excessive amount might be responsible for DNA damage 
in autoimmune diseases. The currently persisting dominant view of Oi" toxicity is that it 
damages cells only indirectly, by giving rise to hydroxyl radical (Halliwell and 
Gutteridge, 1992). However, the seminal work of Fridovich (1986) has demonstrated that 
O2 itself can exert- direct deleterious eflFects in biological systems. A number of 
enzymatic targets of superoxide have been identified. For example, in vitro inactivation 
of ribonucleotide reductase, the key enzyme providing the deoxyribonucleotides required 
for DNA synthesis is lethal for organisms (Gaudu, 1996). 
Superoxide chemistry differs when the reaction is carried out in organic solvents 
and in aqueous solution. In nonpolar environments O2 is a powerful base (proton 
acceptor), nucleophile and reducing agent (Sawyer and Valentine, 1981; Frimer, 1982). It 
can also act as an oxidizing agent, but this ability is only seen with compounds that can 
donate H* ions such as catechol, ascorbate or a-tocopherol (Vitamin-E). In aqueous 
solutions, the basic properties and nucelophilicity of 62" are greatly reduced, as is its 
oxidizing capacity and it acts as a reducing agent. For example, it reduces Fe(III) ions at 
the active site of cytochrome C and Cu(ir) ions at the active site of plastocyanin. Any 
reaction undergone by O2 in aqueous solution will be in competition with the 
dismutation reaction (Halliwell and Gutteridge, 1984). Superoxide radical can reduce 
many metal cations by electron transfer. 
Fe^ ^ + O2" > Fe^ ^ + O2 
Analogous reactions occur with other cation (Mn^ ,^ Cu"*^ )^, chelated iron and many 
enzymes (Valentine, 1979; Wesser et al, 1981). Several workers (Winterboum, 1979; 
1981; Fee, 1982) have argued that this can not occur in vivo because the concentration of 
other biological reducing agents would be greater than that of 02~. 
Sources of superoxide 
Xanthine oxidase has been proposed to be an important source of oxygen derived 
free radicals in reperfused tissue (Granger et al, 1981; Chambers et al, 1985; McCord, 
1985; Hearse et al, 1986). Nascent xanthine oxidase exists as a dehydrogenase using 
NAD"^  as an electron acceptor during the oxidation of hypoxanthine and xanthine (Battel i 
etal, 1972). 
The production of superoxide by ttie mitochondria has been known for nearly 
three decades (Boveris et al, 1976; Turrens and Boveris, 1980). The rate of superoxide 
production by the mitochondria increases when the concentration of oxygen is increased 
or the respiratory chain becomes largely reduced (Turrens et al, 1982). Mitochondria 
produce O2 anion at two sites in the electron transport chain. The first site is the 
ubiquinone to cytochrome Ci step, which passes through the intermediate ubisemiquinone 
(Boveris et al., 1976; Cadenas et al, 1977; Turrens et al, 1985). The second site of 
superoxide anion formation is the NADH dehydrogenase (Turrens and Boveris, 1980). 
The activated NADPH oxidase of phagocytic cells is a potentially large and 
significant source of free radicals in stimulated neutrophils. After inifiafion of the 
respiratory burst, more than 90% of the consumed oxygen can be accounted for by the 
generation of superoxide. Production of O2 and H2O2 by neutrophils is enhanced after 
the cells adhere to surfaces or after being primed with a chemical stimulus (Dahinder 
etal, 1983). 
Biological effects of the superoxide radical 
The superoxide radical, 02~, is formed in all aerobic organisms and systems 
generating it have been observed to kill bacteria, inactivate viruses, damage enzymes and 
membranes, and destroy animal cells in culture (Fridovich, 1978; Halliwell, 1981). 
Bovine liver catalase is inactivated by O2 and H2O2 produced by the aerobic xanthine 
oxidase reaction and this was completely prevented by SOD (Rister and Baehner, 1976). 
Numerous studies of the effects of a O2 flux upon erythrocytes have been 
reported. 1,4-Napthoquinone-2-sulphonate reacts with oxyhemoglobin yielding 
methemoglobin plus 02~ and can be used to increase 0*2" production in erythrocytes 
(Goldberg and Stem, 1976). Studies have implicated both 62" and H2O2 in the lung 
damage caused by hyperoxia. There is one report in which O2 is clearly shown to exert 
an effect, independent of H2O2. Johnson et al (1981) instilled enzymatic sources as well 
as scavengers of O2 and H2O2, directly into the airways of rat lung xanthine oxidase plus 
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xanthine, used as a source of O2 and H2O2, caused damage which was prevented by 
SOD, but not by catalase. 
A number of molecules also react with O2 . Some of these such as epinephrine 
(McCord and Fridovich, 1969), bilirubin (Robertson and Fridovich, 1982), biliverdin 
(Galliani et al, 1984), a-tocopherol and water soluble analogues thereof are clearly 
biologically relevant (Ozawa, 1985). 
Singlet oxygen 
Oxygen in the triplet state (singlet oxygen) is a potent biological toxin. It 
oxidatively damages a variety of biological molecules including DNA (Foote, 1981; 
Straight and Spikes, 1985; Wefers et al, 1987), inactivates viruses (Wefers et al, 1987), 
and, kills both bacteria and mammalian cells (Dahl et al, 1987; Dahl, 1991). Singlet 
oxygen has been found to be a common mediator of photochemical damage in both plants 
and animals. The lifetime of 'O2 within the living cell is very short, of the order of 0.1 
microseconds, while in water and organic solvents it has a relatively longer half life 
(Moan et al, 1979; Firey et al, 1988; Patterson et al, 1990; Moan and Berg, 1991; Baker 
and Kanofsky, 1992). 
Production of singlet oxygen in biological systems 
Singlet oxygen is not a direct product of the enzymatic reactions, but rather a 
secondary reaction product. The two most carefully studied mechanisms for the 
production of singlet oxygen by enzymatic systems are the reaction of hydrogen peroxide 
with hypohalous acid: 
H2O2 + HOX > H^+X"+H2 0+02 ('Ag) (i) 
(where X is chlorine or bromine) and the reaction between two peroxyl radicals: 
2RRHC00 > R R ' C 0 + RRCHOH+O2 ('Ag) (ii) 
In both these mechanism, two highly reactive species must come together to make singlet 
oxygen. Indeed, only one type of living cell, the human eosinophil, produces detectable 
quantities of singlet oxygen (Kanofsky et al, 1988). 
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In human eosinophils, several factors contribute to the efficiency of singlet 
oxygen generation. First, these cells have an extremely active respiratory burst, 
generating 20 finol min"' cell'' of superoxide anion (Kanofsky et al, 1988). Second, 
eosinophils generate hypobromous acid rather than hypochlorous acid (Weiss et al, 
1986). The formation of singlet oxygen by human eosinophils is only 0.4% of the 
available oxygen (Kanofsky et al, 1988). Kanofsky and Sima (1991) found that ozone 
reacts with certain biological molecules to generate singlet oxygen but not all 
biomolecules react with ozone to generate singlet oxygen. 
Photochemical generation of singlet oxygen In biological systems 
Singlet oxygen is believed to be the major mediator of biological damage from a 
number of photosensitizers, including porphyrins, phthalocyanines and halogenated 
fluorescein. Singlet oxygen is produced by a reaction sequence called a Type II 
mechanism: 
p + hX ^ p* (i) 
'p* ^ ^p* (ii) 
V + OzXg' ^ P + 02('Ag) (iii) 
Here p is ground state photosensitizer, 'p* is photosensitizer in an excited singlet state, 
and ^p* is photosensitizer in an excited triplet state. High oxygen concentration favours 
type II mechanism. 
Biological consequences of 'Oi-modified DNA 
The activated oxygen species, including the superoxide anion (O2 ), hydrogen 
peroxide (H2O2), hydroxyl radical (OH) and singlet oxygen can be generated by the 
incomplete reduction of oxygen to water during respiration, by exposure to radiation, 
light, metals, redox active drugs or by release from stimulated macrophages (Sies, 1986), 
because many photosensitizers are biological in origin, and light and oxygen are also 
usually present, 'O2 is a common product in living cells. Allen et al, (1972) were the first 
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to suggest that neutrophils might produce toxic quantities of 'O2 during the respiratory 
burst via a reaction scheme catalyzed by the lysosomal myeloperoxidase. 
H,0, + X- + H^ Myeloperoxidase_^ ^^^ ^^^^ ^^ 
H2O2 + HOX > H2 O + H" + X" + 0, ('Ag) (ii) 
where X is a halide or a pseudohalide ion (SCN). Singlet oxygen behaves like a strong 
electrophile in solution and reacts avidly with molecules possessing regions of high 
electron density, hence, it is clear that oxidative damages to biomoiecules mediated by 
'O2 are rather frequent and DNA, protein or lipids are all at risk (Foote, 1976). 
(a) Reaction with DNA 
In 1989, Floyd and co-workers showed that the photosensitized action of 
methylene blue leads to the effective formation of 8-hydroxyguanine (8-oxodG) in DNA. 
Other photosensitizers known to produce higher yields of 'O2, such as Rose Bengal 
(Floyd et al, 1990) and hematoporphyrin D (Floyd et al, 1990) are also found to lead to 
the formation of 8-oxodG, reinforcing the idea that this lesion is formed by a reaction 
between dG and singlet oxygen. Epe and co-workers (1988) found out that the DNA 
damage profile is completely different from the one caused by hydroxyl radicals. Single 
strand breaks account for less than 5% of the total DNA damage and originate probably 
from superoxide anion formed during endoperoxide decomposition. Contrary to the idea 
that singlet oxygen cannot lead to the direct breakage of the sugar - phosphate backbone 
of DNA. Because of its action at the DNA base level and may be on the sugar phosphate 
backbone, singlet oxygen should be considered as a DNA damaging agent when it is 
generated in the DNA vicinity. The results of Piette et al. (1984) clearly indicate that 
when guanine residues oxidized by singlet oxygen are not removed from DNA they are 
capable of blocking DNA replication, which explains biological properties like the 
transforming or transfecting abilities of DNA that are altered by lesions. 
(b) The cytotoxic action of singlet oxygen 
There are several lines of evidence supporting the idea that singlet oxygen is one 
of the major cytotoxic species to eukaryotic cells (Eisenberg et al, 1984; Dubbelman el 
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ai, 1988), bacteria (Epe et ai, 1989) and viruses (Houba-Herin et al, 1982). It has been 
shown that oxidation of the genetic material by singlet oxygen leads to an important loss 
of the infectivity as DNA replication is strongly impaired in the infected cells (Piette el 
al, 1984) or injection of DNA molecules after phage adsorption does not occur (Bryant 
and King, 1984). Ito (1974) and Kobayashi et al. (1976) have shown that damages 
caused in the nucleus by 'O2 could be, to some extent, responsible for cell inactivation. 
(c) The mutagenic and genotoxic effects of singlet oxygen 
Some evidence showing that 'O2 can promote mutagenic effects has been 
provided from a variety of organisms ranging from yeast (Ito and Kobayashi, 1977) and 
bacteria (Gutter et ai, 1977) to viruses (Piette et ai, 1978). The involvement of 'O2 in 
mutagenesis has been demonstrated by the effectiveness of the reaction, which can be 
reduced by the presence of singlet oxygen quenchers or enhanced by using a deuterated 
medium (Ito, 1974; 1978). It has been demonstrated that guanine oxidation products 
induced by singlet oxygen constitute premutational lesions if they are not repaired 
Decuyper-Debergh et al. (1987). The unreparied quanine oxidation products by singlet 
oxygen can be mutagenic leading to G - • T transversions (Kuchino et al, 1987; Wood et 
al, 1990). Moan et al (1980) have demonstrated that hematoporphyrin and visible light 
can induce genotoxic responses in human NIHK 3025 cells, observed as sister chromatid 
exchanges and single-strand breaks visualized after treatment with alkali. 
(d) Repair of DNA damage induced by singlet oxygen 
DNA modifications induced either by methylene blue photosensitization or by 
chemically generated singlet oxygen have been shown by MUlIer et al. (1990) to be 
recognized and incised by repair endonucleases present in crude bacterial cell extract and 
it appears that only a small fraction of the incised modification are sites of base loss (A-P 
sites) sensitive to exonuclease III, endonuclease IV or to the UV-endonuclease from 
M. luteus. Experiments with purified FPG (formamidopyrimidine-DNA glycosylase) 
confirm that this enzyme is responsible for recognition of singlet oxygen induced DNA 
base oxidation. Czeczot et al (1991) conclude that DNA base modifications (most 
probably 8-oxodG) induced by the photosensitization reaction mediated by methylene 
blue are repaired by FPG protein and Uvr ABC endonuclease. In view of the wide spread 
distribution of 8-oxodG in cellular DNA, the demonstrated miscoding and mutagenic 
properties of this lesion and the existence of a bacterial gene coding for enzyme involved 
in its repair, Tchou et al. (1991) propose that 8-oxodG is the primary physiological 
substrate for a constituent glycosylase found in bacteria and probably in mammalian 
cells. 
Singlet oxygen induces at least four different DNA base modifications 
constituting premutational lesions. If not repaired by glycosylase or endonuclease, these 
DNA damages promote (i) loss of transformation efficiency; (ii) partial inhibition of 
DNA replication and (iii) G to T trans versions. Cytogenetic effects such as sister 
chromatid exchanges in human lymphocytes can also be observed, (summarized in 
Fig. 1.) 
Recently it has been demonstrated that 'O2 is a powerful antithrombotic agent 
through inhibition of coagulation and activation of fibrinolysis (Stief and Fareed, 2000). 
The studies of Stief et al. (2001) have shown that 'O2 generator such as chloramine 
inhibits and reverses platelet aggregation. Singlet oxygen like the prooxidant nitric oxide 
has been shown to inhibit platelet function (Salvemini et al, 1989; Stief e/ al, 2000). 
Photosensitization reaction of drugs leading to the formation of reactive oxygen species 
under ultraviolet radiation (UVR) can cause tissue injury, resulting in damage to various 
cellular macromolecules. Pandey et al (2002) have evaluated the UV-radiation induced 
singlet oxygen generation potential of selected drugs and concluded that synergistic 
action of both can lead to undesirable phototoxic responses. Kim et al (2001) have 
shown that singlet oxygen-mediated damage to SOD and catalase may result in the 
perturbation of cellular antioxidant defence mechanism and subsequently lead to a pro-
oxidant state. 
Biological antioxidant defences 
Under physiological conditions, aerobic organisms consume nearly 98% of 
molecular oxygen at cytochrome aj of the mitochondrial respiratory chain (Chance ei 
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DNA + singlet oxygen 
- Partial inhibition of DNA replication 
- Loss of transformation or transfection 
Mutagenesis (G^T transversion) 
- Sister chromatid exchange 
4,8-dihydro-4-hydroxy-8-oxodG 
Cyanuric acid 
7,8-dihydro-8-oxo guanine 
Can be repaired by: 
- FPGIycosylase 
Uvr ABC endonuclease 
- SOS repair 
Fig. 1. Biological consequences associated with DNA oxidation mediated by singlet 
oxygen 
Adapted from J. Piette 1991, J. Photochem. B: Biol., 11: 241-260. 
al, 1979). During this process, dioxygen is reduced by four electrons, with no release of 
partially reduced oxygen intermediate (Malmstrom, 1982). Nevertheless, there is a 
fraction of O2 (1-2%) not consumed at cytochrome 33 which is mono- or divalently 
reduced to 62" or H2O2. These molecules can attack and irreversibly damage a diverse 
spectrum of biomolecules including proteins, phospholipids, nucleic acids and sugars. 
Aerobic organisms have potent antioxidant defences whose role is to neutralize 
and minimize the potentially cytotoxic and genotoxic effects of reactive oxidants. The 
defences may be primary (that directly decompose or scavange H2O2 and *0H) or 
secondary (which consist of the repair mechanisms that act on biomolecule that have 
undergone oxidative damage). Enzymatic and non-enzymatic antioxidants involved in 
cytotoxicity have been summarised in Tables 2 and 3. 
Autoimmunity 
Autoimmunity is a state wherein the host mounts an immune response to self 
Autoimmune state includes at least four possible permutations (Brickman and Shoenfeld, 
2001). One type of autoimmune state is beneficial to the normal host. A second 
autoimmune state is beneficial to abnormal hosts such as the immune responses to 
transformed cells that occur in patients suffering from malignancies or from intracellular 
infections (Shoenfeld, 1996). A third possibility is the detrimental autoimmune response 
in the abnormal host exemplified by the paraneoplastic syndrome (Lemmark, 1997). The 
immune response to malignant cells cross react with normal tissue antigens causing an 
autoimmune disorders. The fourth autoimmune state is the detrimental immune response 
in an otherwise normal host which results in a classic autoimmune, clinico-pathologic 
condition such as lupus, diabetes or thyroiditis. 
The association of certain serotype of MHC antigens with autoimmune diseases 
has been the subject of extensive investigation. MHC molecules play a key role in the 
presentation of self antigens to T-cell precursors maturing in the thymus during which 
autoreactive clones are eliminated through apoptosis. Hence, MHC antigens determine 
the shaping of the T cell repertoire released to the periphery. A failure of this thymic 
selection could lead to autoimmune diseases. A particular MHC molecule might delete T 
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TABLE - 2 
Antioxidant enzymes involved in cytotoxicity 
Enzyme Reaction and major role 
SOD 
Catalase 
Glutathione peroxidase 
O2 +O2 + 2H^-> H2O2 + O2; scavenging of 
superoxide radicals 
2H2O2 ^ 2H2O + O2 
Breakdown of hydrogen peroxide 
H2O2 + 2GSH -> 2H2O + GSSG 
Decomposition of hydrogen peroxide 
Adapted from Kakkar, P. and Viswanathan, P.N. (1992) J. Sci. Indust. Res. Vol. 51: 802-
809. 
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TABLE - 3 
Non-enzymatic antioxidants involved in cytotoxicity 
Compound / anti-oxidant Effect 
Ascorbic acid 
a-Tocopherol 
Carotenes 
Thiols 
Tryptophan 
Histidine 
Methionine 
Uric acid 
Albumin 
Reducing agent 
Inhibits chain reaction of lipid peroxidation 
Scavenge O2 
Quench 'O2 
Reducing agent 
O2, 'OH scavenger 
O2, *0H scavenger 
'OH scavenger 
'O2, 'OH scavenger in blood plasma 
Binding of copper ions, scavenger of HOCl. 
Adapted from Kakkar, P. and Viswanathiui, P.N. (1992) J. Sci. Indust. Res. Vol. 51: 802-
809. 
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cells that normally suppress autoimmune responses in the periphery or alternatively, 
might allow autoimmune T cell receptor to escape thymic deletion (Mellins, 1992). 
According to Botazzo et al. (1983), an environmental trigger, either a microbe or 
a toxin, leads to tissue damage which releases antigen from sites that were previously 
sequestered from the immune system. Recently it has been shown by Leadbetter et al. 
(2002) in a mouse model of systemic autoimmune disease, the simultaneous activation of 
cell surface antigen receptors and another Cell-like receptor, TLR9, causes a particular 
sub-class of self-immunoglobulin IgG 2a, to be recognized by B cells as if it were a 
pathogen. This triggers T cell-independent proliferation of the B cells. 
Factors associated with autoimmune disease 
Inspite of the enormous progress in the knowledge of immune reactions, the cause 
of autoimmunity is still unknown. Many theories have been proposed to explain the 
origin of autoimmune response. Based on various theories, the possible factors are as 
follows: 
(a) Genetic factors 
Autoimmune diseases show a highly significant familial predisposition. Relatives 
of patients are kno\vn to be at high risk for developing the diseases. A majority of genes, 
which have been associated with autoimmune diseases map within the HLA region. The 
MHC is comprised of three ftmctionally distinct and polymorphic gene clusters: classes 1, 
II and III. Most of the MHC association with SLE, involve class II (HLA-DR and DQ 
alleles) and class III alleles especially null or deficiency alleles of the fourth component 
(C4) of complement (Bias et al, 1986; Goldstein and Arnett, 1987; Braun and Zachary, 
1988; Arnett and Moulds, 1991; Deodhar, 1992). 
(b) Non-MHC genetic factors 
In both animals and humans, autoimmune diseases have been linked to non-MHC 
genetic factors. Fey receptor phenotypes (Oh et al, 1999), DNAse I (Walport, 2000) and 
serum amyloid protein (Sap) genes (Walport, 2000) as well as several apoptosis 
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associated genes (Oh, 1999) are few of the non-MHC factors suspected of predisposing to 
autoimmune diseases. 
(c) Hormonal factors 
Hormones are a significant factor in the development of autoimmune disorders 
(Lahita, 1999; Ahmed, et al, 1999). Patients born with Klinefelter's syndrome (47, 
XX Y), a feminising genotype, also have an unusually high prevalence of lupus (Neu and 
Roy, 1969). Animal models of autoimmune diseases show similar predilections. For 
example, litter bom to NZB mice crossed with NZW mice develop a lupus like illness. 
Hormonal manipulation of NZB/NZW Fl mice effect their disease development such that 
femininisation worsens disease while masculinisation slows diseases progression (Talal, 
1978). Additional hormones including progesterone (Van VoUenhoven, 1994) and 
prolactin (Walker et al, 1998) appear to have immunoregulatory properties. 
(d) Environmental factors 
Environmental factors have been implicated in autoimmune diseases including 
infectious agents, medications, chemicals, toxins, and ultraviolet light (Moar et al., 1998; 
Saraux et al, 1999). Ultraviolet light is known to trigger lupus (McGrath, 1999). 
D-penicillamine a medication formerly used to treat several immune diseases including 
RA, scleroderma and primary biliary cirrhosis has been implicated in the development of 
autoimmune diseases such as lupus and glomerulonephritis (Brik et al, 1995). 
Malignancies are more common in most autoimmune disease than in the general 
population (i.e. lymphomas are 30-40 times more common in primary Sjogren's 
syndrome) (Ramos-Casals et al, 2000) and, conversely, autoimmune manifestations are a 
relatively common paraneoplastic manifestation (i.e. vasculitis, sensory neuronopathy or 
autoimmune encephalomyelitis) (Graus et al, 1986). 
Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
involving both humoral and cellular aspects of the innate and acquired immune systems 
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and is characterized by autoantibodies with a spectrum of specificities that participate in 
disease pathogenesis (Kimberly, 2001). Lupus occurs worldwide and affects females 
more commonly than males (10:1) (Alarcon et ai, 1999). SLE can affect diverse organ 
systems, including the skin, joints, brain, lungs and kidneys. The disease is characterized 
by immune dysregulation, leading to high-level autoantibody production, immune 
complex deposition and vasculitis (Rothfield, 1985). SLE is episodic in its activity and 
variable in severity. The clinical manifestations include fever, an erythematosus 
'butterfly' rash across the face, lesions of discoid lupus or a vasculitic rash, polyarthralgia 
and arthritis, polyserositis (especially pleurisy and pericarditis), anemia, 
thrombocytopenia, renal, neurologic and cardiac abnormalities. One of the impediments 
in understanding human systemic lupus has been its marked heterogeneity (Steinberg et 
al, 1991; Steinberg, 1992). 
The immime system plays a cm c^ial role in the pathogenesis of both active 
inflammatory and non-inflammatory mechanisms of organ damage in SLE. 
Nucleosomes, apoptotic material and efficient pathways for routine, non-immunogenic 
clearance appear pivotal in pathogenesis of SLE (Kimberly, 2001). The etiology of SLE 
is complex, involving both environmental and genetic factors and, likely a synergistic 
relationship between the two. Environmental triggers such as Epstein-Barr virus (James 
et al, 1997), human T cell lymphotropic virus (Brand et al, 1999), hormonal and 
chemical exposure (Cooper et al, 1998), support a gene-environment interaction, and one 
cohort-comparison study supports a gene-gene interaction (Mehrian et al, 1998). SLE is 
highly variable among individual patients and, to some extent, between ethnic group 
since certain disease manifestations seem to cluster within racial populations whereas 
others do not (Petri, 1998). 
The genetic hypothesis in SLE is also supported by the high incidence of SLE in 
patients with certain complement deficiencies (CI, C2 and C4) and associations of 
disease and autoantibody production with HLA class II alleles (Amett, 1997). 
Polymorphisms in low-affinity IgG (fey) receptors, which are important for the clearance 
of immune complexes, are also implicated in the pathogenesis of lupus (Salmon et al, 
1996; Wu et al, 1997). Autoantibodies in family members and their relatives are not 
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directed against the same nuclear antigens. A familial aspecific dysfunction of the B-
lymphocyte is the most likely explanation for autoantibody production in SLE (Michiel 
et al, 2001). Monozygotic, but not dizygotic twins have high concordance rates for SLE 
(Miles and Isenberg, 1993), indicating that genes play an important role in susceptibility. 
Presence of autoantibodies against nuclear antigens is more frequent among non-affected 
family members of patients with SLE than in the general population. This familial 
aggregation suggests that presence of autoantibodies is under genetic control (Llorente el 
al, 1995). 
It has been proposed that lL-10 a pleiotropic cytokine has a key role in the 
pathophysiology of autoimmune disorders such as SLE and the autoimmune 
lymphoproliferative syndrome (Llorente et al, 1994; Fuss et al, 1997). It appears to be 
important in the immune dysfunction seen in SLE patients and their relatives. Increased 
production of IL-10 has been found both in vitro and in vivo in patients with SLE 
(Llorente e/a/., 1993; Llorente era/., 1994; Houssiau e/o/., 1995; Al-Janadi e/a/., 1996; 
Liu and Jones, 1998). IL-10 together with other type 2 cytokines such as IL-6 facilitates 
antibody production (Linker et al, 1991; Spronk, 1992; Llorente et al, 1993; Al-Janadi 
etal, 1993). 
Recent studies suggest that the Cr2 gene, which encodes for complement receptor 
CRl and CR2, is important in disease su,sceptibility. Xiaobo et al (2002) demonstrate 
that abnormalities in CRl and CR2 may be linked to the production of autoantibodies by 
modifying the effect of other systemic lupus erythematosus susceptibility genes. 
Phenotypic expression of other disease manifestations need additional Cr2-independent 
genetic factors (Xiaobo et al, 2002). CRl expression is reduced on erythrocytes, 
polymorphonuclear leukocytes and B lymphocytes in patients with SLE, autoimmune 
hemolytic anemia, and Sjogren's syndrome (Wilson et al, 1986; Fyfe et al, 1987). 
Expression of CR2 on cells is also reduced in patients with SLE (Prodeus et al, 1998). 
Xiaobo et al, (2002) have reported that mutations in the Cr2 gene, especially when 
combined with mutations in the Fas gene, increase the production of autoantibodies. 
Polymorphisms in MHC class II genes have been found to associate with susceptibility 
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for SLE, suggesting that specific MHC-restricted immune responses are involved (Hahn, 
1997). 
004"^ T cell reactive with autoantibody Vw-region peptides play an important role 
in SLE (Waisman et al, 1997). T cells from SLE patients are activated by peptides 
derived from anti-DNA Ig peptides are not the only source of the determinants for anti-
DNA antibody production (Williams, 1995; Linker-Israeli et al., 1996). Nucleosome-
autoreactive T cells also augment anti-DNA production (Mohan and Datta, 1995; Shi el 
al., 1998). It is likely that determinants from several different antigens can activate 
autoreactive T cell help for pathogenic anti-DNA antibody production in SLE. 
Bijl et al. (2002) have concluded that IgGl and IgG2 subclass antibodies to 
nucleohistone and to dsDNA are the predominant subclasses found in plasma of lupus 
patients with renal disease. The frequent occurrence of a rise in IgG2 antinucleohistone 
and IgGl anti-dsDNA antibodies in patients prior to a renal relapse suggests that, besides 
IgGl subclass autoantibodies, IgG2 subclass antibodies to nucleohistone have a particular 
pathophysiological role in lupus nephritis. Heyman et al. (2002) have suggested that 
immune liver disease, mainly autoimmune cholangiopathy, may be an important clinical 
manifestation of SLE. 
Anti-DNA antibodies are heterogeneous showing polyspecificity and cross 
reactivity. Monoclonal antibodies, sera from SLE patients and lupus prone animal models 
show that reactivity may be greater towards denatured forms of DNA (Stollar et al., 
1986). These anti-DNA antibodies recognize epitopes present not only on nucleic acids 
(Andrzejewski et al, 1980; Swanson et al, 1996), but also on nucleoproteins (Stollar, 
1981), proteins (Pisetsky et al, 1985; Wong et al, 1995; Tsuzaka et al., 1996), cell 
membrane structure (Jacob et al, 1986), polysaccharides (Kashihara et al, 1993), 
phospholipids (Tiikainem et al, 1991), erythrocytes, leucocytes, platelets and neurons. 
This polyspecificity of anti-DNA autoantibodies could be due to variable binding sites in 
individual immunoglobulin or to recurrent epitopes in different antigens. The 
polyreactivity of anti-DNA autoantibodies suggest that DNA itself may not be the 
immunogen responsible for what are known as anti-DNA antibodies. Thus, the exact 
antigen responsible for anti-DNA autoantibody production remains an enigma. 
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Apoptosis or programmed cell death is an ongoing process which allows for 
removal of T and B lymphocytes expressing inappropriate receptors, cells which have 
been inappropriately stimulated, as well as damaged or senescent cells (Brickman and 
Shoenfeld, 2001). It also plays an important role in the down regulation of cells, which 
have already undergone appropriate activation and proliferation, a process referred to as 
activation-induced cell death (Bricicman and Shoenfeld, 2001). During the apoptotic 
process, DNA and histones associated with nucleosomes are extruded, intranuclear and 
cellular protein fragments are released by activated caspases, protected intracellular 
antigens are sequestered in apoptotic surface blebs and the bilipid cell membrane is 
flipped inside out exposing phospholipids, including phosphotidyl serine, generally 
hidden from the immune system (Bordron, 1998; Mountz and Zhou, 2001). 
In SLE, greater emphasis involve pathogenic concept, mainly focuses on a 
dysregulation of programmed cell death, giving the immune system the chance to form 
autoantibodies against nuclear constituents like double-stranded DNA or 
ribonucleoproteins (RNP) (Lorenz, 2001). During apoptotic breakdown, many nuclear 
constituents are post-translationally modified, possibly altering antigenicity. Potential 
autoantigens might be sequestered during apoptosis and become accessible for immuno-
competent cells. There might be two major mechanisms which could lead to an increased 
amount of circulating nuclear antigens in SLE patients: an increased amount of apoptosis 
or a decreased clearance of apoptotic cell material appears to an important etiopathogenic 
event in SLE (Lorenz, 2001). Lymphocy1:es of SLE patients with a bacterial infection do 
have an increased amount of spontaneously occurring apoptotic cell death within 
peripheral blood mononuclear cell (Lorenz et al, 1997) which could account for the 
clinical observation, that a flare of SLE could follow an infectious episode (Kreig, 1995). 
Emlen et al. (1994) have demonstrated that the rate of apoptosis of lymphocytes derived 
from SLE patients was 2-3 times faster than that seen in lymphocytes from normal 
controls or patients with rheumatoid arthritis. 
In the case of SLE patients, the impaired clearance of apoptotic cells resulting in 
an accumulation of late apoptotic and secondary necrotic cells including 
oligonucleosomes might lead to an activation of autoreactive T cells with subsequent 
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anti-dsDNA antibodies production (Vol! et al, 1997). It is well established that affinity 
maturation, memory formation and isotype switch are T cell dependent immune 
processes. The similarity of anti-dsDNA response in murine and human SLE strongly 
support the hypothesis of the involvement of T helper cells in the pathogenesis (Lorenz, 
2001). 
Oxygen derived free radicals are known to be involved in the pathobiology of 
SLE, particularly in respect of processes leading to the formation of pathological anti-
DNA antibodies. It has been suggested that activated phagocytic cells release ROS (Allan 
et al, 1988), which penetrate cellular membrane, interact with nuclear DNA and lead to 
its modification (Bashir et al, 1993), Such modification of DNA increases its 
immunogenicity, thus trigerring production of anti-DNA autoantibodies (Blount et al, 
1992). 
Stryer (1988) have shown that mitochondrial hyperpolarization is a likely cause of 
increased ROS production, and may be ultimately responsible for increased spontaneous 
cell death in patients with SLE. Lunec et al (1994) have suggested that SLE patients 
cannot efficiently remove 8-hydroxydeoxyguanine (8-OHdG) from cellular DNA, which 
may result in cell death and release of oxidized DNA. In addition, they have shown that 
denaturation of dsDNA by ROS results in an increased binding of anti-DNA antibodies 
present in sera from SLE patients (Lunec et al, 1989) and that ROS modification of 
human DNA produces a more discriminating antigen for the diagnosis of SLE (Blount et 
al, 1990; Alam et al, 1993). ROS-damaged DNA may, therefore, play a significant role 
in the generation of immime complexes which are of recognized importance in the 
pathogenesis of this disease. 
There is an increasing evidence to suggest a link between autoimmune diseases 
and cancer (Sela and Shoenfeld, 1988; Cash and Klippel, 1991). Petterson et al (1992) 
have shown that cancer, especially lymphoma and soft tissue sarcoma, is more common 
in patients with SLE than in general population. Patients who develop SLE later in life 
seemed most susceptible to cancer, which obviously reflect the higher incidence of 
cancer in older people (Petterson e^  a/., 1992). 
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Cancer 
Carcinogenesis is the malignant transformation of a cell or group of cells (Farber 
and Camerson, 1980; Potter, 1983; Farber, 1984). This multistep process can be divided 
into two main stages, initiation and promotion (Boutwell et al, 1982; Perera, 1991). The 
initiation phase is caused by single exposure to a carcinogenic agent and involves an 
irreversible modification of the genetic material of the cells. On the other hand, 
promotion requires multiple exposure to the promoters to alter gene expression and 
produce a tumour. In contrast to initiation, the promotion stage is reversible (Cerutti, 
1985; Demple, 1990; Martinez-Cayuela, 1995). 
As with other chronic diseases, cancer too has a multifactorial aetiology which 
includes both genetic and environmental factors (Gourley et al, 1992). The 
environmental factors are responsible for 80% to 90% of all human cancers. Genetic 
influence, though long been suspected in incidence of cancer, is less conspicuous and 
more difficult to identify (Clemens, 1991). There is probably a complex inter-relationship 
between hereditary susceptibility and environmental carcinogenic stimuli in the causation 
of a number of cancers. 
Among the environmental factors, consumption of tobacco in various forms (e.g. 
smoking, chewing) is the major cause of cancer of lung, larynx, mouth, pharynx, bladder, 
pancreas and probably kidney (WHO, 1983). Alcohol consumption is associated with 
cancer of oesophagus, liver and rectum (Kabat et al, 1986; Eskelson et al, 1993). 
Dietary factors such as high fat diet, beef consumption, food additives and contamination 
have been related to cancer (Ames, 1983). 
It is a well-known fact that viruses can cause tumors. The genes implicated in 
malignancy are often altered forms of human genes. Often, viruses activate host genes 
that are usually quiescent i.e. the activation of proto-oncogenes into oncogenes, the 
products of which when altered or expressed contribute to malignancy. Apart from 
viruses, mutations too can convert proto-oncogenes into carcinogenic oncogenes. Human 
c-oncogene was found to be mutated, rearranged or unusually active in many viral and 
non-viral tumors. Retroviruses lacking c-onc gene are also oncogenic, giving rise to 
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tumors more slowly than those with v-onc genes (Weiss, 1986). Chromosome 
translocations in human tumor cells brings one genes into juxtaposition with active 
regions for gene expression leading to their constitutive expression (Klein and Kelin, 
1984) and an over expression of the same. Cellular ras genes become oncogenic by point 
mutation resulting in a single codon change (Marshall, 1985). Such minimal change in 
ras can lead to cell transformation in established cell lines. 
Role of ROS in cancer 
The complex series of cellular and molecular changes that occur through the 
development of cancer can be mediated by a diverse endogenous and exogenous stimuli 
(Frenkel, 1992). DNA appears most important in tumor biology since it is firmly 
established that cancer is a genetic disease (Cotran et ai, 1989) and DNA damage is 
thought to be involved in all stages of carcinogenesis (Halliwell and Gutteridge, 1989; 
Vile and Morris, 1992; Olinski, 1993). 
Any agent capable of chemically modifying DNA in cell could be carcinogenic. 
Thus, reactive oxygen species known to cause oxidative damage to DNA are potent 
carcinogens (von Sonntag, 1987a; Halliwell and Aruoma, 1991; Dizdaroglu, 1992; 
Cerutti et al, 1994; Loft and Poulsen, 1996). Although chromatin may offer some 
protection against oxidative damage to DNA (Ljungman and Harawalt, 1992). ROS acts 
at several steps in multistage carcinogenesis (Lunec, 1990; Clayson et al, 1994; Ames et 
al, 1995;Drexere/a/., 1996;Pryor, 1997). 
When the mutations caused by ROS relate to critical genes such as oncogenes or 
tumor suppressor genes, initiation and/or progression of cancer may result (Loft and 
Poulsen, 1996). With respect to cancer, DNA is considered to be the most important 
target of ROS (Feig et al, 1994; Ames et al, 1995). Oxidative damage to DNA includes 
a range of specifically oxidized purines and pyrimidines as well as alkali labile sites and 
strand breaks, formed directly or by repair process (Dizdaroglu, 1994; Breen and 
Murphy, 1995). 
Although, ROS damage all four bases in DNA, mutation are usually related to 
modification of GC base pairs (Retel et al, 1993). The most abundant of the lesions is 8-
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0X0-7, 8-dihydro-2-deoxyguanosine (8-oxodG) (Halliwell and Aruoma, 1993; Toyokuni 
et al, 1994). 8-oxodG is most mutagenic, resulting in G to T transversions (Kuchino et 
al, 1987; Floyd, 1990; Shibutani et al, 1991). The generation of 8-oxodG may account 
for the formation of G -> T transversion through mispairing with adenine. Besides 
misparing, the oxidative products of DNA bases may function in mutagenesis through 
other mechanisms including abnormal interactions with the DNA replicative machinery 
(Feig and Loeb, 1993; Weitzman et al, 1994). Oxidative stress has been implicated as an 
important factor in metastasis, notably because it results in a loss of cell adhesion which 
is the pre-requisite for cellular detachment and host tissue invasion (Fidler and Nicolson, 
1991;Kundue/a/., 1995). 
DNA damage in vivo is constantly repaired by a variety of enzymes. Strand 
breaks are annealed and modified bases are excised out as such or as nucleotides (Demple 
and Harrison, 1994). Defects in DNA repair systems are primarily responsible for several 
human diseases and some of these have been shown to increase cancer risk and increased 
levels of oxidative DNA damage. 
The role of ROS in the development of cancer in humans is further supported by 
the presence of oxidative DNA products in cancer tissue. The concentration of 8-oxodG, 
expressed as the number of molecules/10^ bases, in normal versus cancerous tissue was 
found to be 7.3 versus 23 in lung, 0.94 versus 5.1 in stomach, 3.1 versus 9.2 in ovary and 
2.7 versus 4.4 in colon cancer (Malins and Haimanot, 1991; Olinski et al, 1992; Malins 
et al, 1993). The level of 8-oxodG was much higher in invasive ductal carcinoma of 
female breast than in any other type of cancer (Malins and Haimanot, 1991; Olinski et al, 
1992). Thus, oxidative DNA base damage products are generally higher in cancerous 
tissue. 
Prostrate cancer is characteristically diagnosed in old age or at autopsy and it 
contributes to the third most frequent cancer related cause of death in males in the United 
States. The paucity of known chemical agents associated with prostrate cancer and the 
absence of any apparent environmental or occupational risk factors suggests that prostrate 
cancer is associated with endogenous cellular processes (Feig et al, 1994). The most 
reasonable candidate for endogenously formed genotoxins that accumulate in later life 
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are the reactive oxygen species (Feig et al, 1994). Chronic hepatitis is associated with 
the presence of inflammatory cells, presumably generating ROS. The 8-oxodG content in 
liver with chronic hepatitis has been found to be significantly higher than the content in 
normal liver (Shimoda et al, 1994). Oxygen free radicals are also implicated in the 
mechanism of gastric (Salim, 1992a) and colonic cancers (Salim, 1992b). 
Objectives of the present study 
Systemic lupus erythematosus (SLE) is an autoimmune disease of indeterminate 
etiology that predominantly afflicts women in the childbearing age. Anti-DNA antibodies 
play a very important role in the clinical manifestations of SLE, especially nephritis, most 
likely by immune complex deposition. The central role of anti-DNA antibodies in SLE 
has led to intense investigation into the mechanism underlying this response, in both 
patients as well as inbred mice developing lupus like illnesses. The review of literature 
makes it evident that oxidative DNA damage is an important carcinogenic factor and 
plays a vital role in the pathogenesis of both SLE and cancer. 
In the present study, commercially obtained double stranded calf thymus DNA 
was purified free of proteins and subjected to digestion with micrococcal nuclease to 
obtain 200 bp fragments. These fragments were modified with singlet oxygen and 
superoxide anion radical generated by riboflavin and 365 nm UV light. 
The '02-02~-DNA fragments were characterised by various physiochemical 
techniques and employed in competitive assay to delineate the antigen binding 
characteristics of induce antibodies against 'O2-O2 -DNA. The free radical modifications 
on DNA were studied by UV spectroscopy, thermal denaturation studies, nuclease Si 
digestibility and fluorescence spectroscopy. 
Antigenicity of 'O2- 02~-DNA was probed by inducing antibodies in rabbits. 'O2-
O2 -DNA was foimd to be highly immunogenic as assessed by direct binding ELISA. 
The specificity of induced antibodies was evaluated by competition ELISA and gel 
retardation assay. 
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Anti 'O2 -O2 -DNA antibodies were used as probes for immunochemical 
detection of oxidative damage in DNA isolated from various cancer patients. 
Alternatively, circulating antibodies in sera of cancer and SLE patients were 
characterized for their binding towards native and 'O2-O2 -DNA. 
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MATERIALS 
Calf thymus DNA, nuclease SI, micrococcal nuclease, riboflavin, superoxide 
dismutase, bovine serum albumin, agarose, anti-human/anti-rabbit IgG-alkaline 
phosphatase and FITC conjugates, ethidium bromide, Coomassie Brilliant Blue G-250 
and R-250, sodium dodecyl sulphate, Freund's complete and incomplete adjuvants, 
methylated bovine serum albumin, Tv/een-20, Triton X-100, nitroblue tetrazolium, 
sodium azide, para-nitrosodimethyl aniline were purchased from Sigma Chemical 
Company, U.S.A. Protein-A agarose from Genei, synthetic polynucleotides and Ficoll 
400 were obtained from Pharmacia Fine Chemicals, Sweden. EDTA (disodium salt), 
chloroform and isoamyl alcohol were from Qualigens, India. 
Polystyrene microtitre flat bottom ELISA plates having 96 wells (7 mm diameter) 
were purchased from NUNC, Denmark. QIAamp blood midi kit from Qiagen, 
p-nitrophenyl phosphate and Folin-Ciocalteau reagent were obtained from Centre for 
Biochemical Technology, New Delhi. Acrylamide, ammonium persulphate, 
bisacrylamide, N,N,N',N'-tetramethylethylene diamine (TEMED) were from Bio-Rad 
Laboratory U.S.A. EDTA (disodium salt), hydrogen peroxide, chloroform, isoamyl 
alcohol, methanol, glacial acetic acid were from Qualigens, India. Diphenylamine and 
ethanol were chemically pure. All other chemicals were of highest analytical grade 
available. 
Equipments 
Shimadzu UV-240 Spectrophotometer equipped with thermo-programmer and 
controller unit, ELISA microplate reader, Elico pH meter model LI-120, ultraviolet lamp 
(Vilber Lourmat, France), agarose gel electrophoresis assembly (GNA-100); Beckman 
ultracentriftige, Avanti 30 table top high speed refrigerated centrifuge (Beckman, 
U.S.A.); polyacrylamide gel electrophoresis assembly (Bio-Rad, U.S.A.) and fluorimeter 
(Hitachi, Japan) were the major equipments used in this study. 
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Collection of sera 
SLE sera were obtained from outdoor and indoor patients of the Department of 
Medicine, All India Institute of Medical Sciences, New Delhi, showing high titre anti-
DNA antibodies and fulfilled the American College of Rheumatology criteria for the 
diagnosis of SLE (Amett et al, 1988). Normal human sera were obtained from healthy 
individuals and stored in small aliquots at -20°C. Sera of cancer patients proven with 
histopathological diagnosis were obtained from J.N. Medical College Hospital A.M.U.. 
Aligarh. Sera were decomplemented by heating at 56°C for 30 min and stored in aliquots 
at -20°C. 
METHODS 
Purification of calf thymus DNA 
Commercially obtained calf thymus DNA was purified free of proteins and single 
stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was dissolved in 
0.1 X SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, pH 7.3) and then 
mixed with an equal volumes of chloroform-isoamyl alcohol (24:1) in a stoppered 
container and gently mixed occasionally for 1 hr. The aqueous layer containing DNA was 
separated from the organic layer and re-extracted with chloroform-isoamyl alcohol. The 
DNA was precipitated with two volumes of cold absolute ethanol and collected on a glass 
rod. After drying in air, the DNA was dissolved in acetate buffer (30 mM sodium acetate 
containing 30 mM zinc chloride, pH 5.0) and treated with nuclease SI (150 units/mg 
DNA) at 37°C for 30 min to remove single stranded regions. The reaction was stopped by 
adding one-tenth volume of 200 mM EDTA, pH 8.0. The nuclease SI treated DNA was 
extracted twice with chloroform-isoamyl alcohol and finally precipitated with two 
volumes of cold ethanol. The precipitate was dissolved in phosphate-buffered saline 
(PBS) (10 mM sodium phosphate containing 150 mM sodium chloride), pH 7.4. 
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Fragmentation of purified native calf thymus DNA 
Micrococcal nuclease was used to digest purified DNA to obtain smaller 
fragments (AH et al, 1985). Purified DNA (2 mg/ml) in 6 mM Tris, 100 mM NaCl and 2 
mM CaCl2, pH 8.0 was treated with 0.25 units of micrococcal nuclease per mg DNA at 
37°C for 6 min. The reaction was stopped by adding one-tenth volume of 200 mM 
EDTA, pH 8.0. The mixture was extracted twice with chloroform-isoamyl alcohol and 
fragmented DNA was precipitated with cold absolute ethanol and dissolved in 30 mM 
acetate buffer, pH 5.0 containing 30 mM ZnC^. The DNA was digested with nuclease Si 
(150 units/mg DNA) at 37°C for 30 min. The reaction was stopped with one-tenth 
volume of 200 mM EDTA, pH 8.0. The digested DNA fragments were extracted twice 
with chloroform-isoamyl alcohol and precipitated with cold absolute ethanol. The DNA 
fragments were then dissolved in TBS (0.01 M Tris, 0.15 M NaCl) pH 8.0 and separated 
on the basis of size by gel filtration on Sepharose 4B column (46.0 cm x 1.2 cm) 
equilibrated with TBS. Fractions of 4 ml were collected. The size of the DNA fragments 
was determined by PAGE. 
Polyacrylamide gei electrophoresis 
Nucleic acid samples were subjected to PAGE under non-denaturing conditions as 
described by Laemmli (1970). The foUov/ing stock solutions were prepared: 
(a) Acrylamide-bisacrylamide (30:0.8) 
30 gm acrylamide and 0.8 gm bisacrylamide was dissolved in distilled water to a 
final volume of 100 ml. The solution was filtered and stored at 4°C in an amber colored 
bottle. 
(b) Resolving gel buffer 
36 gm Tris was dissolved in 48 ml of 1 N HCl, pH adjusted to 8.8 and final 
volume made upto 100 ml with distilled water. 
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(c) Electrode buffer 
The electrophoretic buffer used was TAE, pH 7.9 (40 mM Tris, 1.14 ml glacial 
acetic acid and 1 mM EDTA). 
(d) Procedure 
The PAGE assembly was set up and the glass plates separated by 1.5 mm thick 
spacer were sealed with 1% agarose from the sides and bottom. The non-denaturing gel 
was prepared and poured between the glass plates and allowed to polymerize at room 
temperature. Nucleic acid samples were mixed with one-tenth volume of'stop mix' (30% 
Ficoll, 0.025% xylene cyanol FF and 500 mM EDTA in 10 times concentrated TAE 
buffer) and applied onto the gel. The gel was electrophoresed for 8-10 hr at room 
temperature at 80 volts, stained with ethidium bromide (0.5 |ig/ml) and visualised under 
UV light. 
Recipe for 7.5% non-denaturing PAGE 
Acrylamide-bisacrylamide 10.0 ml 
Resolving gel buffer 5.0 ml 
1.5% ammoniimi persulphate 1.5 ml 
Distilled water 23.5 ml 
TEMED 20.0 ^1 
Polyacrylamide gel electrophoresis for proteins 
Polyacrylamide slab gel electrophoresis was performed under denaturing 
conditions as described by Laemmli (1970). The following stock solutions were prepared: 
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(a) Acrylamide-bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
bisacrylamide in distilled water to a final volume of 100 ml. 
(b) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48.0 ml of IN 
HCl. The contents were mixed, pH adjusted to 8.8 and the final volume brought to 100 
ml with distilled water. 
(c) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH titrated to 6.8 with IN 
HCl and the final volume adjusted to 100 ml with distilled water. 
(d) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, 
pH adjusted to 8.3 and final volume made up to one litre. 
(e) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% agarose. The 
resolving gel mixture was prepared by mixing the components in the appropriate volume 
and poured into the space between the glass plates leaving sufficient space at the top for 
the stacking gel. After the polymerization of separating gel, stacking gel mixture was 
poured and allowed to solidify. Protein samples containing 10% glycerol and 0.002% 
bromophenol blue were applied and electrophoresis was carried out at 60V for 6-8 hrs. 
Staining of the gel was achieved with 0.1% Coomassie Brilliant Blue R-250 (in 25% iso-
propanol and 10% glacial acetic acid). Destaining was carried out in a 10% mixture each 
of acetic acid and methanol. 
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Recipe for 7.5% SDS-PAGE 
1.25 ml 
2.5 ml 
-
5.65 ml 
0.1 ml 
0.5 ml 
0.75 ^ 1 
7.5 ml 
-
3.75 ml 
16.95 ml 
0.3 ml 
1.5 ml 
15.0^1 
Solutions Stacking gel Resolving gel 
Acrylamide-bisacrylamide 
Stacking gel buffer 
Resolving gel buffer 
Distilled water 
10%SDS 
1.5% ammonium persulphate 
TEMED 
Determination of DNA concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Diphenylamine (2 g) was dissolved in 200 ml boiling hexane. After adding 0.5 g 
of activated charcoal, the hot mixture was filtered through Whatman No 1 filter paper 
and the filtrate was kept overnight at 4°C and dried at room temperature before use. 
(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial acetic 
acid and 0.75 ml concentrated sulphuric acid. The reagent was prepared fresh before use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and 
incubated at 70°C for 15 min. 100 i^l of 5.43 mM acetaldehyde was added followed by 
2.0 ml of freshly prepared diphenylamine reagent. The contents were mixed and 
incubated at room temperature for 16-20 hr. Absorbance was read at 600 nm and the 
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concentration of DNA in unknown samples was determined from a standard plot of 
purified calf thymus DNA. 
Determination of protein concentration 
Protein was estimated by the methods of Lowry et al. (1951) and Bradford 
(1976). 
Protein estimation by Folin's-phenol reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), Cu '^ 
ions (to chelate proteins) and tartarate (to keep the Cu^ ^ ions in solution at high pH). 
(a) Folin-Ciocalteau's reagent 
The reagent was purchased from Centre for Biochemical Technology, New Delhi 
and diluted 1:4 with distilled water before use. 
(b) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) Two percent sodium carbonate, 100 mM sodium hydroxide, 
(ii) 0.5 percent copper sulphate in 1 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) and 
(ii) in the ratio of 50:1. 
(c) Procedure 
To 1 ml of protein sample was added 5 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. 1 ml of working Folin-Ciocalteau's reagent 
was added and the tubes were read at 660 nm after 30 min. The concentration of protein 
in imknown sample was determined from a standard plot of bovine senmi albumin. 
Protein estimation by dye-binding method 
This assay is based on color change when Coomassie Brilliant Blue G-250 in 
acidic medium, binds strongly to protein hydrophobically and at positively charged 
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groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue color is observed (Xniax-595 nm). 
(a) Dye preparation 
100 mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol 
and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution was 
diluted to a final volume of 1 litre and filtered through Whatman No. 1 filter paper to 
remove undissolved particles. 
(b) Protein assay 
To 1 ml of solution containing 10-100 fig protein was added 5 ml of dye solution 
and contents mixed by vortexing. The absorbance was read at 595 nm after 5 min against 
a reagent blank. 
Modification of calf thymus DNA by free radicals 
Purified calf thymus DNA was modified by superoxide anion radical and singlet 
oxygen. Superoxide anion radical was detected by photosensitized reduction of nitroblue 
tetrazolium G^BT), leading to the formation of a blue colored product, nitroblue 
formazan (Nakayama et al, 1983). Production of superoxide radical was confirmed by 
monitoring the inhibition of formation of blue colored product in the presence of 
superoxide dismutase (SOD). 
Formation of singlet oxygen was measured in aqueous solution by monitoring the 
bleaching of p-nitrosodimethylaniline (pRNO) (Kraljic and Moshni, 1978). Production of 
singlet oxygen was confirmed by monitoring the bleaching of pRNO in presence of 
sodium azide (NaNs), a specific quencher of singlet oxygen. 
DNA fi-agments of around 200 bp were modified by the method of Naseem e( al. 
(1988). A total volume of 3.0 ml contained, 100 fig/ml DNA, 50 mM potassium 
phosphate buffer, pH 7.8, 0.1 mM EDTA, 0.06% Triton X-100 and 40 [iM riboflavin. 
Immediately after mixing, the reaction was carried out in the presence of UV light 
(365 nm) at room temperature. The samples were dialyzed extensively to remove 
riboflavin and Triton X-100. 
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Spectroscopic analysis 
(a) The ultraviolet spectra of modified and unmodified 200 bp DNA were recorded in 
the wavelength range of 200-400 nm on a Shimadzu UV-240 spectrophotometer. 
(b) The modification incurred on DNA fragments was also analyzed by UV-
difference spectroscopy. 
(c) Fluorescence emission spectroscopy of native and modified 200 bp DNA samples 
using ethidium bromide was performed on a fluorimeter. 
Absorption - temperature scan 
Thermal denaturation analysis of nucleic acids was performed in order to 
ascertain the degree of modification incurred on the nucleic acids by determining mid 
point melting temperature (Tm). Native and modified samples were subjected to heat 
denaturation on a Shimadzu UV-240 spectrophotometer coupled with a temperature 
programmer and controller assembly (Hasan and Ali, 1990). All the samples were melted 
from 30°C to 95°C at a rate of 1.5°C / min after 10 min equilibration at 30°C. The change 
in absorbance at 260 nm was recorded with increasing temperature. Percent denaturation 
was calculated as follows: 
A - A Percent denaturation = — ^- x 100 
Amax ~ A30 
Where, Aj = Absorbance at a temperature T°C. 
Amax = Final maximum absorbance on the completion of 
denaturation (95°C). 
A30 = Initial absorbance at 30°C. 
Nuclease SI digestibility 
Native and modified DNA were characterized by nuclease SI digestibility 
(Matsuo and Ross, 1987). One microgram each of native and modified DNA in acetate 
buffer (30 mM each of sodium acetate and zinc chloride, pH 5.0) were treated with 
nuclease SI (20 units/ng DNA) for 30 min at 37°C. The reaction was stopped by adding 
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one-tenth volume of 200 mM EDTA, pH 8.0. The digested and control samples were 
subjected to agarose gel electrophoresis. 
(a) Gel preparation 
Agarose (1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 2 mM 
EDTA) was dissolved by heating. TTie solution was cooled to about 50°C and then 
poured into gel tray and allowed to solidify at room temperature. 
(b) Sample preparation and loading 
Native and modified DNA samples treated with nuclease SI were mixed with 
one-tenth volume of sample buffer (0.125% bromophenol blue, 30% Ficoll 400, 500 mM 
EDTA in lOX electrophoresis buffer). The samples were loaded in the wells and 
electrophoresed for 2 hr at 30 mA. The gels were stained with ethidium bromide (0.5 
^g/ml), viewed by illumination under UV light and photographed. 
Immunization schedule 
Native and modified DNA (100 |xg) were complexed with an equal volume (w/w) 
of methylated BSA and emulsified with an equal volume of complete Freund's adjuvant 
and injected intramuscularly in female rabbits. Subsequent injections were given in 
incomplete Freund's adjuvant. Each animal received a total of 800 }ag of antigen in the 
course of 8 injections. Blood was collected from marginal vein of the ear, serum was 
separated and decomplemented by heating at 56°C for 30 minutes. Pre-immune serum 
was collected prior to immunization. The sera were stored in small aliquots at -20°C with 
0.1% sodium azide as preservative. 
Isolation of IgG by Protein-A agarose 
Serum IgG was isolated by affinity chromatography on Protein-A agarose 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was applied to column 
(12 X 45 mm) equilibrated with the same buffer. The wash through was recycled 2-3 
times. Unbound IgG was removed by extensive washing with PBS, pH 7.4. The bound 
IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride (Coding, 1976) and 
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neutralized immediately with 1 ml of IM Tris-HCl, pH 8.5. Three ml fractions were 
collected and read at 251 and 278 nm. The IgG concentration was determined considering 
1.4 OD280 = 1.0 mg IgG/ml. The isolated IgG was dialyzed against PBS, pH 7.4 and 
stored at -20°C with 0.1% sodium azide. 
Immunological detection of antibodies 
Level of antibodies was evaluated by immunodiffusion, enzyme linked 
immunosorbent assay and gel retardation assay. 
(a) Immunodiffusion 
Immunodiffusion (ID) was carried out by Ouchterlony's double diffusion system. 
Six ml of 0.4% molten agarose in PBS containing 0.1% sodium azide was poured on to a 
glass petridishes and allowed to solidify at room temperature. Wells of 5 mm diameter 
were cut into hardened gel and an appropriate concentration of antigen and antibody was 
placed in the wells. The petridishes were allowed to stand in a moist chamber at room 
temperature for 48-72 hr. The gels were washed with 5% sodium citrate to remove non-
specific precipitin lines. The resuh was analyzed visually. 
(b) Enzyme linked immunosorbent assay 
The following reagents were prepared in distilled water and used in enzyme 
immunoassay. 
(i) Buffers and reagents 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl 
pH 7.4, containing 500 i^ l Tween 20/L. 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 mM 
magnesium chloride. 
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Citrate-phosphate buffer 
50 mM citric acid, 50 mM Na2HP04, pH 5.0. 
Substrate 
500 \xg p-nitrophenyl phosphate (p-NPP)/ml carbonate-bicarbonate buffer, pH 
9.6. 
(ii) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as solid 
support (Aotsuka et al, 1979). One hundred microlitre of 2.5 fag/ml antigen in TBS, pH 
7.4 was coated in test wells of microtitre plates, incubated for 2 hr at 37°C and overnight 
at 4°C. The antigen coated wells were washed three times with TBS-T to remove 
unbound antigen. Unoccupied sites were blocked with 150 \i\ of 1.5% BSA in TBS for 
4 - 5 hrs at room temperature. The plates washed once with TBS-T and antibody (100 
^1/well) to be tested, were diluted in TBS and added to each well. After 2 hr incubation at 
37°C and overnight at 4°C, the plates were washed four times with TBS-T and an 
appropriate anti-immunoglobulin alkaline phosphatase conjugate was added to each well. 
After incubation at 37°C for 2 hr, the plates were washed four times with TBS-T and 
three times with distilled water and developed using p-nitrophenyl phosphate substrate 
respectively. The absorbance was recorded at 410 nm on an automatic microplate reader. 
Each sample was run in duplicate. The control wells were treated similarly but were 
devoid of antigen. Results were expressed as a mean of Atest -Acontroi-
Competition ELISA 
The antigenic specificity of the antibodies was determined by competition ELISA 
(Hasan et al, 1991). Varying amount of inhibitors (0-20 ^g/ml) were mixed with a 
constant amount of antiserum or IgG. The mixture was incubated at room temperature for 
2 hr and overnight at 4°C. The immune complex thus formed was coated in the wells 
instead of the serum. The remaining steps were the same as in direct binding ELISA. 
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Percent inhibition was calculated using the formula 
Percent inhibition = 1 - ^'°'"'"'"' x 100 
•^uninhibited 
Band shift assay 
For the visual detection of antigen-antibody binding and immune complex 
formation, gel retardatioii a.ssay was performed (Sanford et ai, 1988). A constant amount 
of antigen (native and modified DNA) was incubated with varying amounts of IgG in 
PBS, pH 7.4 for 2 hr at'37°C and overnight at 4°C. One-tenth volume of 'stop mix' dye 
was added to the mixture and electrophoresed on 1% agarose for 2 hr at 30 mA in TAE 
(40 mM Tris, 5 mM sodium acetate, 1 mM EDTA) buffer, pH 7.9. The gels were stained 
with ethidium bromide (0.5 }ig/ml), visualized under UV light and photographed. 
Isolation of human-DNA 
Human DNA was isolated from whole blood using QIAamp Blood Midi Kit 
supplied by QIAGEN, U.S.A. Blood was collected in presence of anticoagulant (EDTA). 
Procedure 
To 2 ml of whole blood was added 200 \i\ protease stock solution and 2.4 ml 
buffer AL. Contents were mixed by vortexing and incubated at 70°C for 10 min. Two ml 
ethanol (95-100%) was added the contents were again mixed by vortexing. Half of the 
solution (~3.3 ml) was transferred into the Midi column with centrifligation tube and was 
spinned at 3000 rpm for 3 min. The filtrate was discarded. The remaining half of the 
sample was transferred to the same Midi Column and the whole procedure repeated. The 
Midi colimm was washed with 2 ml of buffer AWl and centrifuged at 5000 rpm for 1 
min. Two ml of buffer AW2 was added and the column centrifuged again at 5000 rpm for 
15. The Midi column was placed in a fresh 15 ml centrifuge tube. 300 pi of buffer AE 
was added onto the Midi column, incubated at room temperature for 5 min and 
centriftiged at 5000 rpm for 5 min. This step was repeated once with 300 pi buffer AE. 
The pooled filtrate contain human DNA. The absorbance of DNA solution was read at 
260 nm and 280 nm to ascertain its purity and concentration. 
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Photochemical generation of superoxide anion radical and singlet 
oxygen species 
Singlet oxygen and superoxide anion radicals were generated by illumination of 
riboflavin with UV light (365 nm). Tlie generation of superoxide anion was monitored by 
nitroblue tetrazolium (NBT) assay. In order to optimize the superoxide generation, the 
time of illumination and dose dependent response of riboflavin and Triton X-100 was 
studied. The results showed an increase in absorbance at 560 nm with increasing time 
period of illumination. It is evident from the curve that 20 min of illumination of UV 
light caused optimum generation of superoxide radical (Fig. 2). Similarly, dose dependent 
experiments were carried out with varying amounts of riboflavin (Fig. 3) and Triton X-
100 (Fig. 4). The ability of riboflavin to form singlet oxygen ('O2) was determined by 
monitoring the bleaching of pRNO (Joshi, 1985; Fig. 5). 
The generation of these radicals was further confirmed by the use of their 
respective quenchers i.e. SOD for superoxide anion radical (O2") and sodium azide for 
singlet oxygen ('O2). The evidence for the formation of ('O2) was obtained by examining 
the progress of the reaction in presence of sodium azide (NaNs), a specific quencher for 
O2. A near complete inhibition of 'O2 production was observed (Fig. 6). Dose dependent 
experiment was carried out with varying concentration of NaNs (0, 10, 15, 25, 50, 75, 
100 mM). Maximum inhibition was obtained at 100 mM (Fig. 7). Superoxide dismutase 
was used to further confirm the production of superoxide anion radical. No inhibition in 
the formation of blue coloured product (nitroblue formazan) was observed due to the 
presence of singlet oxygen in the system (Fig. 8). Inhibition in the formation of nitroblue 
formazan was observed when both SOD and NaNa, quencher of singlet were used 
(Fig. 9). 
Commercially available calf thymus DNA was purified free of proteins, RNA and 
single stranded regions and digested with micrococcal nuclease to obtain DNA 
fi-agments. The digested DNA was subjected to gel filtration on Sepharose 4B column 
(Fig. 10). Alternate fi-actions on PAGE resulted in DNA of varying size (Fig. 10 inset). 
The fi-action(s) of 200 bp (average size) was selected for these studies. 
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Fig. 2. Time dependent generation of superoxide (O2 ) anion radical by riboflavin in 
light (A), in dark (•), without Triton X-100 (O), without riboflavin (A). 
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Fig. 3. Superoxide anion radical generation under varying concentrations of 
riboflavin. 
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Fig. 6. Effect of sodium azide (MaNs) on generation of 'O2 by riboflavin in light (O) 
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Fig. 7. Quenching of O2 with increasing concentrations of sodium azide. 
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Modification of DNA by superoxide anion radical and singlet oxygen 
species 
DNA fragments of average size of 200 bp in 50 mM potassium phosphate buffer, 
pH 7.8, 0.1 mM EDTA, 0.06% Triton X-100, 40 |iM riboflavin was illuminated for 1 hr 
under 365 nm UV light at room temperature. The 'O2-O2-DNA samples were dialyzed 
against PBS, pH 7.4 to remove riboflavin and Triton X-100. 
Characterization of 'O2-O2-DNA 
Figure 11 shows the UV absorption spectra of superoxide radical and singlet 
oxygen species modified DNA with characteristic hyperchromicity. The spectra shows a 
shift of approximately 10 nm towards longer wavelength side at both X,max and X,min for 
'02-02~-DNA relative to native DNA. The percent hyperchromicity was 30% in 1 hr 
illuminated sample. 
The modifications incurred on nDNA fragments was also analyzed by UV 
difference spectroscopy (Fig. 11 inset). The spectral curve exhibited an appreciable 
negative inversion in absorption between 240-260 nm, followed by increased absorption 
at 270 nm. Moreover the spectral curve also exhibited a shoulder at around 290 nm. 
Elimination of the characteristic 260 nm peak is indicative for the loss of the double 
helical structure of DNA. These changes in the curve are also indicative of the possible 
generation of single stranded regions and ring opening of the nucleic acid bases as a 
consequence of the modification. 
Native and ^02-02~-DNA was used to record fluorescence spectra. The decrease 
in the fluorescence intensity was observed probably indicating the generation of strand 
breaks due to lesser amount of ethidium bromide intercalation in modified DNA as 
compared to native DNA (Fig. 12). 
DNA was modified in presence and absence of NaNs, Figure 13 shows the UV 
absorption spectra of native DNA, '02-02~-DNA and '02-02"-DNA in presence of NaNj. 
Approximately 50% quenching in the absorbance was observed. 
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Fig. 11. Ultraviolet absorption spectra of 200 bp native DNA and O2-O2 -DNA. 
Native DNA (—), 'O2-OV-DNA (—-). Inset: Ultraviolet difference 
spectroscopical scanning of O2 -O2 -DNA, native DNA served as control. 
58 
3 
< 
Z 
U 
O 
2 
liJ 
O 
U) 
Li 
(T 
O 
70.0 
600 650 
WAVELENGTH (nm) 
700 
Fig. 12. Fluorescence emission spectra of EtBr ( ), native DNA (— )^ and O2-O2 
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Thermal melting of 'O2-O2 -DNA 
Thermally induced transitions were measured spectrophotometrically at 260 nm 
by heating nucleic acid samples at a rate of 1.5°C per min. Melting curves were recorded 
at temperatures from 30°C to 95°C. Increase in UV absorption at 260 nm was taken as a 
measure of denaturation. Figure 14 shows the thermal denaturation profile of native and 
'O2-O2 -DNA. The melting temperature of native DNA at which 50% of the double 
helical structure is lost was found to be 86°C, while in case of 'O2-O2 -DNA it was found 
to be 78°C. The results exhibit a net decrease of 8°C in the Tm value for the '02-02"-
DNA when compared to its unmodified native conformer. These findings indicate, 
therefore, that the decrease in Tm to the extent of 8°C is primarily due to structural 
alteration of DNA which occurs upon generation of single strand breaks and base 
modifications. The percent hyperchromicity and the values of native and O2-O2 -DNA 
are shown in Table 4. 
Nuclease SI digestibility 
Native and '02-02~-DNA were digested with nuclease SI (20 units/|j,g DNA) for 
30 min. The resulting DNA sample was subjected to agarose gel electrophoresis. The 
controls were the unmodified DNA samples with and without nuclease SI treatment. The 
results showed substantially decreased intensity in case of SI treated 'O2-O2 -DNA 
compared to non-Sl treated control. However, some loss in fluorescence intensity was 
observed in unmodified native DNA (Fig. 15). 
Antigenicity of ^Oj-Oj-DNA 
The antigenicity of the '02-0*2 -DNA was probed by inducing antibodies in 
rabbit. The induction of antibodies and their specificity was assayed by direct binding and 
competition ELISA. The binding of these antibodies to the immunogen and native DNA 
was further substantiated by band shift assay. 
The antibodies raised against 'Oi-Oj'-DNA was found to be non-precipitating in 
immunodiffusion. Direct binding ELISA was used to characterize the immune response 
61 
TEMPERATURE( C) 
Fig. 14. Thermal melting profile of native DNA (O) and 'O2-O2 -DNA (•). 
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TABLE - 4 
Ultraviolet and thermal denaturation characteristics of native and 
^02-02-DNA under identical experimental condition 
Parameters Native DNA 'Oi-Oa'-DNA 
Absorbance ratio (A260 / A280) 1.8 1.6 
Percent hyperchromicity at 95°C 36.7 17.2 
Melting temperature (Tm), °C 86.0 78.0 
Onset of duplex melting, °C 65.0 58.0 
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Fig. 15, Nuclease SI digestibility of native and 'O2-O2-DNA. Lane 1 contained 
native DNA, while lane 2 contained native DNA treated with nuclease SI. 
Lane 3 contained 02-02~-DNA, while lane 4 contained O2-O2 -DNA 
treated with nuclease SI. Electrophoresis was carried out on 1% agarose gel 
for 2 hr at 30 niA. 
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in rabbits following immunization with '02-02~-DNA. The anti-serum showed a titre of 
1:25600 (Fig. 16). The antibodies against native DNA complexed with methylated BSA 
was also raised in rabbits. The results evaluated by direct binding ELISA showed 
negligible binding. Preimmune serum as control did not show appreciable binding with 
the immunogen. The specificity of the induced antibodies for antigenic determinants on 
'O2-O2-DNA was evaluated by competitive binding assays. A maximum of 70% 
inhibition in antibody binding was recorded at an inhibitor ('02-02~-DNA) concentration 
of20|ag/ml(Fig. 17). 
(a) Purification and binding characteristics of immune IgG 
Immunoglobulin G was isolated from preimmune and immune rabbit serum by 
affinity chromatography on Protein- A Agarose column (Fig. 18). The purity of the IgG 
was evaluated by SDS-polyacrylamide gel electrophoresis in absence of a reducing agent. 
The purified IgG migrated as a single band upon electrophoresis (Fig. 18 inset). 
Direct binding ELISA of the purified IgG showed a strong reactivity with the 
immunogen (Fig. 19). Preimmune IgG as negative control showed negligible binding to 
'02-02~-DNA. 
(b) Antigenic specificity of anti- O2-O2 -DNA antibodies 
The anti-'02-02~-DNA antibodies exhibited a broad specUiim of reactivity as 
demonstrated by inhibition assay using the immunogen, nucleic acids, synthetic 
polynucleotides, chondroitin sulphate, cardiolipin and chromatin as inhibitors. A 
maximum of 84.5% inhibition of anti-'02-02~-DNA IgG with immunogen as an inhibitor 
was observed (Fig. 20). Fifty percent inhibition was achieved at an inhibitor 
concentration of 1.9 |ig/ml. Competition experiments with native DNA showed 
considerable inhibition in antibody activity. Pre-incubation of immime antibody with 
native DNA inhibited its binding to •02-0*2'-DNA by 47.8% at 20 ng/ml (Fig. 20). ROS-
DNA, 200 bp DNA showed a maximum inhibition of 50.25%, 32.3% at 20 ^g/ml. 
respectively (Fig. 20). 
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Fig, 16. Direct binding ELISA of ' 02-0*2 -DNA with preimmune (A) and immune 
sera (A). Microtitre plate was coated with 'O2-OV-DNA (2.5 |xg/ml). 
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Fig. 17. Inhibition ELISA of immune (0) and preimmune (A) serum antibodies with 
•02-02"-DNA. The microtitre plate was coated with '02-02 -DNA 
(2.5 ^g/ml) and the serum dilution was 1:100. 
67 
1.50 
E 
c 
o 
CO 
N 
f -
< 
Ui 
0 
z 
< 
CD 
0 
t/> 
ffi 
< 
1,00 
0.50 
0.00 
8 10 12 
FRACTION NUMBER 
Fig. 18. Elution profile of mili-'02-02 -DNA IgG on Protein - A Agarose column. 
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Fig. 20. Inhibition of immune IgG binding to O2 -O2 -DNA. The competitors were 
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Native chromatin, ROS-chromatin, cardiolipin and chondroitin sulphate were 
used as inhibitors of antibody activity. Native chromatin and ROS-chromatin showed a 
maximum inhibition of 7.9% and 12.5% respectively. Cardiolipin and chondroitin 
sulphate inhibited antibody binding to antigen to the extent of 37% and 48%, respectively 
(Fig. 21). 
To further define the structural determinants recognized by anti-'Oa-Oa -DNA 
antibodies, their interactions with various synthetic polymers were studied. Poly(dA-
dU).poly(dA-dU) showed maximum inhibition of 12.7% at a concentration of 20 fig/ml, 
whereas, poly(dI-dC).poly(dI-dC) and poIy(dA-dT).poly(dA-dT) showed maximum 
inhibitions of 38.7% and 44.4%, respectively (Fig. 22). Table 5 summarises the results of 
the inhibition studies of the anti-'02-0'2"-DNA antibodies with various inhibitors. 
Band shift assay 
The visual detection of antigen antibody interaction was performed by band shift 
assay. Constant amounts of native and 'O2-O2-DNA were incubated with varying 
amounts of immune IgG for 2 hr at room temperature and overnight at 4°C. The resulting 
immune complexes were then electrophoresed on 1% agarose for 2 hr at 30 mA. 
Figure 23 shows the binding of IgG to 'O2-O2 -DNA. As clearly evident, with an increase 
in the amount of IgG, there was an increase in the formation of high molecular weight 
immune complexes, which resulted in retarded mobility with a subsequent decrease in the 
fluorescence intensity of antigen. 
Binding characteristics of human anti-DNA autoantibodies to 
'O2-O2-DNA 
The binding pattern of SLE anti-DNA autoantibodies to native and '02-02"-DNA 
was determined by direct binding ELISA. All the 24 sera showed appreciable binding to 
native and '02-0'2~-DNA. Preferentially high binding was observed in case of 'O2-O2"-
DNA. Figures 24 and 25 shows the enhanced binding to SLE anti-DNA autoantibodies 
(1:100 serum dilution) with '02-02~-DNA as compared to native DNA. With normal 
human sera no appreciable binding was observed. 
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Fig. 21. Inhibition of immune Ig(j binding to '02-0*2~-DNA. The competitors were 
cardiolipin (•), chondroitin sulphate (A), chromatin (A), 'OH-modified 
chromatin (O). The microtitre plate was coated with 'O2-O2 -DNA 
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Fig. 22. Inhibition of immune IgG binding to 'O2-O2 -DNA. The competitors were 
poIy(dI-dC).poIy(dI-dC) (A), poiy(dA-dU).poly(dA-dU) (A), poiy(dA-
dT).poly(dA-dT) (O). The microtitre plate was coated with 'O2-O2 -DNA 
(2.5 ^ g/ml). 
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TABLE - 5 
Antigenic specificity of *02-02 -DNA IgG 
Inhibitor Maximum % inhibition at 20 \igfml 
'02-02'-DNA 
Native DNA 
200 bp DNA 
ROS-200 bp DNA 
Poly (dA-dU). poly (dA-dU) 
Poly (dl-dC). poly (dl-dC) 
Poly (dA-dT). poly (dA-dT) 
Chondroitin sulphate 
Cardiolipin 
Native chromatin 
ROS modified chromatin 
84.5 
47.8 
32.3 
50.25 
12.7 
38.7 
44.4 
48.0 
37.0 
7.9 
12.5 
The microtitre plates were coated with modified DNA (2.5 |ig/ml). 
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Fig. 23. Band shift assay of anti-'02-02~-DNA IgG binding to (a) native DNA and 
(b) '02-02"-DNA. Native DNA and '02-02"-DNA (Ifig) each were 
incubated with 10,20,40 and 60 ^g of IgG for 2 hr at 37°C and overnight at 
4°C. Electrophoresis was performed on 1% agarose gel for 2 hr at 30 niA. 
Lane 1, contains native or '02-02'-DNA, while lanes 2,3,4, and 5 contain 
native or O2 -O2 -DNA with increasing concentrations of IgG. 
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Fig. 24. Direct binding ELISA of SLE sera to native DNA ( ^ ) , and 'O2 -O2 -DNA 
i^M)- Normal human sera (NHS) served as negative control. Serum dilution 
was 1:100. 
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Fig. 25. Direct binding ELISA of SLE sera to native DNA {W7/}\ and 'O2 -0*2'-DN A 
(^^) . Normal human sera (NHS) served as negative control. Serum dilution 
was 1:100. 
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Antigenic specificity of SLE autoantibodies 
Competition ELISA was also performed to further evaluate the specificity of each 
SLE sera for native and '02-02~-DNA (Figs 26-37). The antibody was incubated with 
increasing concentrations (0-20 }ig/ml) of inhibitors (native or '02-0'2~-DNA). Out of 24 
SLE sera tested 'O2-O2 -DNA showed higher degree of recognition by 17 sera and 
inhibited their activity to a maximum of 77%. On the other hand native DNA was found 
to be less reactive for the same samples showing a maximum inhibition of 50%. 
However, one sample showed greater recognition towards native DNA as compared to 
'O2-O2 -DNA. The results of this study, summarised in Table 6 shows 'O2-O2 -DNA as a 
better inhibitor for 23 SLE sera. 
Purification of SLE and cancer sera IgG 
SLE and cancer sera IgG were purified by affinity chromatography on Protein- A 
Agarose. Protein A has been known to bind IgG from most of the mammalian species. 
The purified IgG eluted in a single symmetrical peak (Fig. 38). Their purity was checked 
by SDS-PAGE under non-reducing conditions which resulted in a single band (Fig. 38 
inset). 
Band shift assay 
Band shift assay was employed to visualize the interaction of native and ' 02-02-
DNA with SLE IgG. A constant amount (1 fig) of antigen was incubated with varying 
amounts of SLE IgG (0-80 |ig) for 2 hi' at 37°C and overnight at 4°C. These immune 
complexes were then electrophoresed on 1% agarose for 2 hr at 30 mA. An increase in 
the IgG concentration caused an increase in the immune complex formation which 
resulted in a relative increase in the molecular weight and consequently retarded mobility 
(Fig. 39). 
78 
Z 
o 
h 
ffl 
X 
z 
h 
Z 
Ul 
o 
lU 
Q. 
100 
0.01 0.1 10 100 
INHIBITOR CONCENTRATION (jug/ml) 
Fig. 26. Inhibition ELISA of SLE anti-DNA autoantibodies froni SLE sera (1 and 2). 
The inhibitors used were native DNA (A,0), and '02-0*2"-DNA (A,»). The 
microtitre plates were coated with '02-02~-DNA (2.5 [ig/ml) and serum 
dilution was 1:100. 
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Fig. 27. Inhibition ELISA of SLE anti-DNA autoantibodies froni SLE sera (3 and 4). 
The inhibitors used were native DNA (A,0), and '02-0*2"-DNA (A,«). The 
microtitre plates were coated with '02-02"-DNA (2.5 ^g/ml) and serum 
dilution was 1:100. 
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Fig. 28. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (5 and 6). 
The inhibitors used were native DNA (A,0), and '02-02"-DNA (A,»). The 
microtitre plates were coated with 'O2-O2 -DNA (2.5 |ag/ml) and serum 
dilution was 1:100. 
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Fig. 29. Inhibition ELISA of SLE anti-DNA autoantibodies froni SLE sera (7 and 8). 
The inhibitors used were native DNA (A,0), and '02-0*2"-DNA (A,#). The 
microtitre plates were coated with O2-O2 -DNA (2.5 ng/ml) and serum 
dilution was 1:100. 
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Fig. 30. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (9 and 
10). The inhibitors used were native DNA (A,0), and '02-02"-DNA (A,»). 
The microtitre plates were coated with '02-02~-DNA (2.5 fig/ml) and serum 
dilution was 1:100. 
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Fig. 31. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (11 and 
12). The inhibitors used were native DNA (A,0), and 'O2 -0*2~-DNA (A,«). 
1 * — 
The microtitre plates were coated with O2 -O2 -DNA (2.5 fig/ml) and serum 
dilution was 1:100. 
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Fig. 32. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (13 and 
14). The inhibitors used were native DNA (A,0), and '02-0*2"-DNA (A,«). 
The microtitre plates were coated with O2 -O2 -DNA (2.5 |ig/ml) and serum 
dilution was 1:100. 
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Fig. 33. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (15 and 
16). The inhibitors used were native DNA (A,0), and 'O2-OV-DNA (A,»). 
The microtitre plates were coated with O2 -O2 -DNA (2.5 \ig/ml) and serum 
dilution was 1:100. 
86 
)d 25 
Z 
0 
h i 
X 
z 
H 
Z 
UJ 
0 
X 
u 
a 
50 
75 
100 I I I I M i l l I I I I I I I I 
0.01 0.1 10 100 
INHIBITOR CONCENTRATION (pg/ml) 
Fig. 34. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (17 and 
18). The inhibitors used were native DNA (A,0), and 'Oi-OV-DNA (A,»). 
The microtitre plates were coated with O2 -O2 -DNA (2.5 ^g/ml) and sewm 
dilution was 1:100. 
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Fig. 35. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (19 and 
20). The inhibitors used were native DNA (A,0), and 'Oi-O'i'-DNA (A,«). 
The microtitre plates were coated with O2 -O2 -DNA (2.5 |ig/ml) and serum 
dilution was 1:100. 
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Fig. 36. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (21 and 
22). The inhibitors used were native DNA (A,0), and •02-02"-DNA (A,«). 
The microtitre plates were coated with O2 -O2 -DNA (2.5 ^g/ml) and serum 
dilution was 1:100. 
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Fig. 37. Inhibition ELISA of SLE anti-DNA autoantibodies from SLE sera (23 and 
24). The inhibitors used were native DNA (A,0), and '02-02"-DNA (A,«). 
The microtitre plates were coated with '02-02~-DNA (2.5 pig/ml) and serum 
dilution was 1:100. 
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TABLE-6 
Competitive inhibition data of SLE sera 
Sera no. 
Maximum percent inhibition at (20 ng/ml) 
Native DNA '02-02'-DNA 
1 39.0 70.1 
2 28.3 68.6 
3 15.0 21.4 
4 27.0 45.0 
5 29.0 40.0 
6 46.0 66.5 
7 48.0 77.0 
8 23.7 58.7 
9 35.4 61.6 
10 16.0 57.7 
11 23.5 59.0 
12 26.0 52.0 
13 50.0 75.9 
14 30.0 41.5 
15 34.7 39.7 
16 46.0 59.0 
17 23.3 69.1 
18 14.4 55.6 
19 27.0 37.0 
20 12.0 21.0 
21 16.0 23.0 
22 25.0 29.0 
23 16.0 25.0 
^ 4 28^0 24.0 
Microtitre plates were coated with '02-02~-DNA (2.5 )ig/ml). 
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Fig. 38. Elution profile of SLE (•) and lung cancer IgG (A) on Protein-A Agarose 
column. Inset; Purity of (a) isolated SLE IgG and (b) cancer IgG on 7.5% 
SDS-PAGE. 
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Fig. 39, Band shift assay of SLE IgG binding to (a) native DNA and (b) 'O2-O2"-
DNA. Native DNA and '02-02~-DNA (l|ig) each were incubated with 
10,20,40 and 80 ^g of IgG for 2 hr at 37X and overnight at A%\ 
Electrophoresis was carried out on 1% agarose gel for 2 hr at 30 mA. Lane 1 
contains native or '02-02~-DNA, while lanes 2,3,4, and 5 contain native or 
O2-O2 -DNA with increasing concentrations of SLE IgG. 
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Recognition of native and modifled antigens by cancer antibodies 
The study comprised 30 sera from patients suffering from cancer of different 
organ and organ systems. Sera from normal, healthy individuals served as control. 
Cancer sera were obtained after careful clinical examination of patients with 
histopathological diagnosis attending J.N. Medical College Hospital, A.M.U., Aligarh. 
The binding of circulating antibodies in cancer sera (at 1:100 serum dilution) with native 
and '02-02'-DNA was assessed by direct binding ELISA. All the sera tested showed 
higher recognition to '02-02~-DNA (Fig. 40). The binding specificity of antibodies in 
cancer sera were analysed by competitive binding assay (Table 7). The samples contained 
5 sera of lung cancer. All the sera showed greater recognition of '02-02~-DNA than 
native DNA. The maximum inhibition observed was 60.8%, 61.3%, 65.3%, 66.8%) and 
70.7%) with 'O2-O2-DNA (Fig. 41). The results indicated higher binding of antibodies in 
lung cancer sera towards 'O2-O2-DNA than native DNA. 
Five sera were collected from patients with cancer of urinary bladder. All five 
sera showed higher inhibition of 59.3%, 52.6%, 55.4%, 55.4%, 68.75% with 'O2-O2'-
DNA over native DNA (Fig. 42). Four sera were from patients suffering from breast 
cancer. All sera showed greater inhibition with '02-02"-DNA 59%, 46%>, 50.7%, 53.6%. 
where as, with native DNA all four sera showed inhibition below 40%) (Fig. 43). 
Among four sera from cancer of head and neck, two sera showed higher inhibition 
of 65%o and 67.2% with '02-02~-DNA while two sera showed a moderate inhibition of 
45% and 48.5% (Fig. 44). 
Four sera were collected from patients suffering from oral carcinoma. Among 
them, two sera showed 69.6% and 65.6%) inhibition with '02-02~-DNA and one sera 
showed greater inhibition with native DNA 46%) and 40% inhibition with '02-02~-DNA 
while one sera showed moderate inhibition with '02-02~-DNA 48%) (Fig. 45). 
Four sera from gall bladder cancer showed 39.66%, 42.8%o, 45%) and 41% 
inhibition with '02-02"-DNA and 20.8%, 25.6%), 27% and 28%o inhibition with native 
DNA (Fig. 46). 
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Fig. 40. Binding of various cancer sera to native ( ^ ^ ) and 'O2 -O^^ -DNA (^M). 
Normal human sera (NHS) serve as negative control. The histograms show 
mean absorbance values for binding of NHS and sera from patients with 
cancer of lung (1), urinary bladder (2), breast (3), head and neck (4), oral (5). 
gall bladder (6), prostrate (7), vulva (8), CML (9), Hodgkin's (10). 
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Fig. 41. Detection of autoantibodies against native and 02-02"-DNA, in the sera of 
patients with cancer of lung, (a) Cancer sera 1,2 and 3 by native DNA 
(A,0,0), and '02-0*2";DNA (A,#,f). (b) Cancer sera 4 and 5 by native 
DNA (A,0) and 'O2-O2 -DNA (A,t). The microtitre plates were coaled 
with 'O2 -02~-DNA (2.5 |ig/ml) and serum dilution was 1:100. 
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Fig. 42. Detection of autoantibodies against native and O2 -O2 -DNA, in the sera of 
patients with cancer of urinar)' bladder, (a) Cancer sera 1,2 and 3 by native 
DNA (A,0,V), and '02-0*2"-DNA (A,«,T). (b) Cancer sera 4 and 5 by 
native DNA (A,0) and 'O2-OV-DNA (A,»). The microtitre plates were 
coated with O2 -O2 -DNA (2.5 jig/ml) and serum dilution was 1:100. 
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Fig. 43. Detection of autoantibodies against native and '02-02~-DNA, in the sera of 
patients with breast cancer, (a) Cancer sera 1 and 2 by native DNA (A,0), 
and '02-q2"-DNA (A,«). (b) Cancer sera 3 and 4 by native DNA (A,0) 
and '02-02"-DNA (A,#). The microtitre plates were coated with '02-0i~-
DNA (2.5 i^ g/ml) and serum dilution was 1:100. 
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Fig. 44. Detection of autoantibodies against native and O2 -O2 -DNA, in the sera of 
patients with cancer of head and neck, (a) Cancer sera 1 and 2 by native 
DNA (A,0), and 'O2-OV-DNA (A,t). (b) Cancer sera 3 and 4 by native 
DNA (A,0) and 'Oi-OV-DNA (A,«). The microtitre plates were coated 
with 'O2-0V-DNA (2.5 |ig/ml) and serum dilution was 1:100. 
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Fig. 45. Detection of autoantibodies against native and O2 -O2 -DNA, in the sera of 
patients with oral cancer, (a) Cancer sera 1 and 2 by native DNA (A,0), and 
'02-02~-DNA (A,»). (b) Cancer sera 3 and 4 by native DNA (A,0) and 
'02-02^-DNA (A,«). The microtitre plates were coated with '02-02'-DNA 
(2.5 |xg/ml) and serum dilution was 1:100. 
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Fig. 46. Detection of autoantibodies against native and 'Oa-Oi'-DNA, in the sera of 
patients with cancer of gall bladder, (a) Cancer sera 1 and 2 by native DNA 
(A,0), and '02-02~-DNA (A,«). (b) Cancer sera 3 and 4 by native DNA 
(A,0) and ^02-02''-DNA (A,»). The microtitre plates were coated witli 
'O2 -O'a'-DNA (2.5 i^g/ml) and serum dilution was 1:100. 
Four sera were collected from patients suffering from prostrate cancer. Three sera 
showed maximum inhibition of 25.8%, 37%, 45.4%) with O2-O2 -DNA and one sera 
1/ showed almost equal percent inhibition (32% and 31%)) with native and O2-O2 -DNA 
(Fig. 47). 
One serum sample each from Hodgkin's lymphoma and CML showed higher 
recognition for '02-0'2~-DNA with maximum inhibition of 65%) and 45%). Two serum 
samples from carcinoma of vulva showed higher recognition for 'O2-O2-DNA with 
maximum inhibition of 68% and 54%) as compared to native DNA 45% and 35% 
(Fig. 48). The binding data of cancer sera are shown in Table 7. 
Band shift assay 
The binding of native and '02-02'-DNA to lung cancer IgG was detected by band 
shift assay. Constant amounts of antigen were incubated with varying amounts of cancer 
IgG for 2 hr at room temperature and overnight at 4°C. The immune complexes were then 
electrophoresed on \% agarose for 2 hr at 30 mA (Fig. 49). The gel visualized under UV 
light revealed formation of high molecular weight immune complexes which resulted in 
retarded mobility and decrease in fluorescence intensity of the nucleic acid on agarose 
gel. 
Detection of oxidative lesions in DNA 
DNA was isolated from lymphocytes of various cancer patients. The purity and 
concentration of the DNA preparations were ascertained by A26oand A2go measurements. 
DNA isolated from lymphocytes of normal healthy individuals were used as controls for 
this study. 
Anti-'02-02"-DNA IgG was used as probe to detect oxidative lesions in the DNA 
from cancer patients. Immune complexes, formed by incubating a fixed amount (60 i^ g) 
of anti-'02-02 -DNA IgG with increasing concentrations (0 to 20 |ig/ml) of DNA were 
coated on microtitre plates already coated with 'O2-O2-DNA (2.5 ^g/ml). 
Two DNA samples isolated from patients with lung cancer (Fig. 50) showed a 
high inhibition 64%) and 68.6%) of immune IgG binding to immimogen. Another two 
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Fig. 47. Detection of autoantibodies against native and O2-O2 -DNA, in the sera of 
patients with prostrate cancer, (a) Cancer sera 1 and 2 by native DNA (A,()), 
and '02-0*2~-DNA (A,«). (b) Cancer sera 3 and 4 by native DNA (A,0) 
and '02-02"-DNA (A,»). The microtitre plates were coated with 'O2-O2 -
DNA (2.5 ng/ml) and serum dilution was 1:100. 
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Fig. 48. Detection of autoantibodies against native and 'O2 -02"-DNA, in the sera of 
patients with Hodgkin's lymphoma, CML, cancer of vulva, (a) Hodgkin's 
lymphoma and CML with native DNA (A,0), and 'O2-OV-DNA (A,»). 
(b) Cancer of vulva (sera 1 and 2) by native DNA (A,0) and '02-02'-DNA 
(A,»). The microtitre plates were coated with '02-d'2~-DNA (2.5 ^g/mi) 
and serum dilution was 1:100. 
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TABLE - 7 
Inhibition of the binding of antibodies in cancer sera to ^Oi-O'i'-DNA by 
native and *02~0*2'-DNA 
Type of cancer 
Lung 
Urinary bladder 
Breast 
Head and neck 
Oral 
Gall bladder 
Prostrate 
Vulva 
CML 
Hodgkin's 
No. of sera tested 
5 
5 
4 
4 
4 
4 
4 
2 
1 
1 
Maximum percent 
Native DNA 
32.3, 16.5,39.3, 15, 
20.4 
38.6,32.8,35.6,32.9, 
45 
39.7,28.5,24.5,30.2 
39.9,35.7,40.7,43 
34.4, 38.7, 46,42 
20.8, 25.6, 27, 28 
32, 18.6,23.7,41.9 
45,35 
28 
50 
inhibition at 20 fig/ml 
'02-02~-DNA 
65.3,61.3,70.7,66.8, 
60.8 
59.3, 52.6, 55.4, 55.4, 
50 
59,46,50.7,53.6 
65,67.2,45,48.5 
69.6, 65.6, 40, 48 
39.7,42.8,45,41 
31,25.8,37,45.4 
68,54 
45 
65 
The microtitre plates were coated with O2-O2 -DNA (2.5 fxg/ml) and serum dilution was 
1:100. 
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Fig. 49. Band shift assay of cancer IgG binding to (a) native DNA and (b) O2-O2'-
DNA. Native DNA and '02-02'-DNA (lf.ig) each were incubated with 
10,20,40 and 80 \ig of IgG for 2 hr at 37^C and overnight at 4X\ 
Electrophoresis was carried out on 1% agarose gel for 2 hr at 30 mA. Lane I 
contains native or '02-02~-DNA, while lanes 2,3,4, and 5 contain native or 
02~02 -DNA with increasing concentrations of cancer IgG. 
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Fig. 50. Inhibition of binding of aiiti-'02-02 -DNA IgG by genomic DNA isolated 
from lymphocytes of patients with cancer of lung. The microtitre plates were 
coated with 'O2-OV-DNA (2.5 |ag/ml). The curves (A) and (A) represent 
DNA isolated from two different individuals with cancer of lung. 
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samples of DNA were from oral cancer (Fig. 51). These DNA samples showed a high 
inhibition of 61.1% and 60% in antibody binding. Two DNA samples isolated from 
cancer of prostrate showed inhibition 42.7%) and 37% of antibody activity (Fig. 52). On 
the contrary, DNA isolated from two normal healthy individuals showed negligible 
inhibition of 20%) and 25%) with anti-'02-0'2"-DNA IgG binding to the immunogen 
(Fig. 53). These resuhs have been summarised in Table 8. 
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Fig. 51. Inhibition of binding of anti-'Oi-OV-DNA IgG by genomic DNA isolated 
from lymphocytes of patients with oral cancer. The microtitre plates were 
coated with '02-02"-DNA (2.5 ng/ml). The curves (A) and (A) represent 
DNA isolated from two different individuals with oral cancer. 
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Fig, 52. Inhibition of binding of anti-'02-0*2 -DNA IgG by genomic DNA isolated 
from lymphocytes of patients with prostrate cancer. The microtitre plates 
were coated with '02-d2"-DNA (2.5 ^g/ml). The curves (A) and (A) 
represent DNA isolated from two different individuals with prostrate cancer. 
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Fig. 53. Inhibition of binding of anti-'02-0V-DNA IgG by genomic DNA isolated 
from lymphocytes of normal individuals. The microtitre plates were coated 
with 'O2-OV-DNA (2.5 |ig/ml). The curves (A) and (A) represent DNA 
isolated from two different individuals. 
TABLE - 8 
Binding of anti-^02-02~-DNA IgG to DNA isolated from lymphocytes of 
cancer patients 
Type of cancer No. of sera tested Maximum percent 
inhibition at 20 fig/ml 
Lung 
64.8 
68.0 
Oral 
61.1 
60.0 
Prostrate 
42.8 
37.0 
The microtitre plates were coated with O2-O2 -DNA (2.5 |ig/ml) 
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In the living cells, ROS are formed continuously as a consequence of both normal 
metabolic activity as well as external factors. The damage from these free radical has 
been proposed to be involved in carcinogenesis and various degenerative diseases 
(Halliwell and Aruoma, 1991; Ames et al, 1995; Pryor, 1997). ROS modify DNA at 
various sites that include base damage (Dizdaroglu et al, 1991) leading to mutations 
(Moody and Hasan, 1982; Brawn and Fridovich, 1985). Although, aerobes have 
developed antioxidant defence to control harmful effects of activated oxygen species 
(Lunec and Blake, 1990; Sandstrom and Buttke, 1993; Singh et al 1994) a certain 
fraction escapes the cellular defences. This can happen if antioxidants are depleted and/or 
if the formation of reactive oxygen species is increased beyond the ability of the defence 
to cope with them (Sies, 1991). Induction of mutation following DNA damage represents 
a failure of the repair system to remove DNA damage and is one of the critical events in 
carcinogenic transformation and other human pathologies (Henley and Liim, 1997; 
Moller and Wallin, 1998). 
Singlet oxygen generated by various photosensitization reactions is a reactive 
oxygen species (ROS) involved in a variety of biological functions such as gene 
expression, photoaging and apoptosis (Grether-Beck et al, 1996; Ryter and Tyrrell, 
1998; Zhuang et al, 1999; Krutmann, 2000). DNA is one of the main targets of 'O2 and 
the abundance of oxidative DNA damage poses two biological problems: (i) blocking of 
DNA synthesis, which is lethal; and (ii) miscoding, which is premutagenic. It has been 
demonstrated that 'O2 reacts preferentially with guanine residues either as free 
nucleosides (Cadet et al, 1983) or as components of the DNA molecule (Menck et al, 
1993), yielding a variety of DNA lesions selectively at guanine sites. These include DNA 
cleavage (Devasagayam et al, 1991), alkali and piperidine-labile sites (including abasic 
sites) (Blazek et al, 1989), cyanuric acid (Cadet et al, 1983), 2,6-diamino-4-oxo-5-
formamidopyrimidine (Fapy G, a guanine derivative with an open imidazole ring) 
(Boiteux et al, 1992) and 7,8-dihydro 8-oxodeoxyguanine (8-oxodG) (Floyd et al, 
1989). DNA damage profile of 'O2 is completely different from the one caused by 
hydroxyl radicals. As compared to 'OH radical 'O2 causes fewer strand breaks (Epe et al, 
1988). 
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Superoxide is the most abundant reactive species generated in vivo by several 
enzymatic and non-enzymatic pathways in mammalian tissue (Fridovich, 1986; 
Devasagayam et al, 1991; Sies and Menck, 1992). It has been implicated in several 
disease states and unfavourable alteration of tissues and biomolecules (McCord, 1985; 
Cross, 1987; Epe et al, 1988). It has been demonstrated that Oi" itself can exert 
deleterious effect in biological systems (Fridovich, 1986). It is possible that superoxide 
radical produced in excessive amounts might be responsible for DNA damage in 
autoimmune diseases. 
Systemic lupus erythematosus (SLE) is a highly variegated and pleomorphic 
autoimmune disease (Andrzejewski et al, 1980) of unknown etiology. It is characterized 
by the presence of anti-DNA autoantibodies of multiple specificities to numerous self-
components which includes nuclear and cytoplasmic antigens (Tan, 1989; Pisetsky, 
1994). The marked heterogeneity of SLE autoantibodies has been one of the impediments 
in understanding the disease. Both genetic and environmental factors are believed to 
contribute to this disease (Steinberg et o/., 1991). The presence of anti-DNA 
autoantibodies in the sera of SLE patients has long been considered as a marker of SLE 
as well as the pathogenic factor for its renal disease manifestations (Koffler, 1974). 
The binding diversity of lupus autoantibodies to a whole spectrum of modified 
nucleic acid conformer (Ali et al, 1991; Alam and Ali, 1992; Alam et al, 1992; 1993; 
Anfet al, 1994; Klinman et al, 1994; Ahmad et al, 1997; Garg and Ali, 1998) seems to 
be enormous. The studies to imderstand the origin and consequence of anti-dsDNA 
antibodies are still in progress. For these reasons, it was thought desirable to investigate 
the immunogenicity of '02-02~-DNA and its possible role in SLE and development of 
cancer. 
Cancer, the biological consequence with the most complex etiology, has been 
implicated in free radical induced damage to DNA (Ames et al, 1993a; 1995). Despite 
enzymatic repair and other defences, continuous ROS damage and division of cells with 
unrepaired and misrepaired lesions lead to mutations. If these relate to critical genes such 
as oncogenes or tumor suppressor genes initiation and/or progression of cancer can occur. 
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In the present study, 200 bp calf thymus DNA was modified by singlet oxygen 
and superoxide anion radicals generated by illumination in presence of riboflavin. This 
study shows that the damage observed by illumination of riboflavin system in a metal 
free solution is due to the production of singlet oxygen ('O2) and superoxide anion radical 
(O2"). The production was confirmed by the use of quenchers, sodium azide and SOD. 
Near complete inhibition in the production of 'O2 was observed in presence of sodium 
azide. No inhibition in the production of O2 was observed when SOD alone was used. 
However inhibition in the production of O^' was observed when both SOD and sodium 
azide were used. This could be due to the reason that when SOD is exposed to a singlet 
generating system it becomes susceptible to oxidative modification and damage as 
indicated by the loss of activity (Kim, et ai, 2001) and hence SOD alone could not 
inhibit the production of 02~ but when sodium azide was also introduced in the system at 
a concentration at which almost complete inhibition of 'O2 production was observed, 
SOD was not inactivated and inhibition in the production of O2 was observed. 
The photochemical reaction of a free radical with DNA resulted in an increase in 
absorption at 260 nm with a peak shift of 10 nm towards longer wavelength side in both 
Apiax and Xmin- This could be attributed to single strand breaks and modification of bases. 
The UV difference spectral curves exhibited appreciable perturbation in native 
DNA as a consequence of photochemical modification. The spectral curve exhibited an 
appreciable negative inversion in absorption between 240 nm - 260 nm, followed by 
increased absorption at 270 nm. Moreover the spectral curve also exhibited a shoulder at 
around 290 nm. Elimination of the characteristic 260 nm peak is indicative for the loss of 
the double helical structure of DNA due to loss of DNA helical organization, single 
strand breaks and modification of bases. These changes in the curve are also indicative of 
the possible ring opening of the nucleic acid bases as a consequence of the modification. 
UV absorption spectra of '02-02~-DNA is presence of sodium azide shows that 
the damage obtained in presence of quencher of 'O2 may be due to the presence of O^ 
only. 
The fluorescence spectra of '02-02^-DNA showed decrease in fluorescence 
intensity as compared to native DNA, which indicates the generation of strand breaks as 
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lesser amount of ethidium bromide gets intercalated in modified DNA as compared to 
native DNA. 
The thermal denaturation profile of native and '02-02~-DNA showed a net 
decrease of 8°C in the Tm value for '02-02"-DNA as compared to its native conformer. 
This may be due to structural alteration of DNA which occurs upon generation of single 
strand breaks and base modifications. Base stacking and hydrogen bonding interaction 
are known to stabilize the native structure of DNA, thus high temperature which disrupts 
these interactions favours denaturation of DNA (Casperson and Voss, 1983; Thomas. 
1993). The lowered melting temperature of ROS-DNA suggests reduced base stacking. 
single strand breaks, disruption of hydrogen bond and a consequent helix disruption in 
DNA following attack by ROS. 
Earlier studies demonstrate the structural alteration in DNA following damage by 
various agents and may be large enough to be recognized by single strand specific 
nucleases (Slor and Lev, 1973; Kato and Fraser, 1973; Shisido and Ando, 1974; 
Yamasaki et al, 1977). In view of this, native and '02-02~-DNA were subjected to 
nuclease SI digestion. The results, showed partial digestion of '02-02~-DNA on 
treatment with nuclease SI, while native DNA remained undigested. This observation 
clearly demonstrates that sufficient single strand breaks are generated in DNA by ROS 
rendering it susceptible to digestion by single strand specific nuclease SI. 
Native XMkper se is a weak immunogen, (Madaio et al, 1984; StoUar, 1986). 
However, its oxidatively damaged analog with altered bases and conformational variance 
from B-form can trigger immune response (Lafer et al, 1981; Lee et al, 1984; Santella et 
al, 1985; Sundquist et al, 1987; Moinuddin and Ali, 1994; Hasan et al, 1995). Double-
stranded RNA, RNA-DNA hybrid, left handed Z-DNA, triple helical RNA and DNA 
analogues and double helical polydeoxyribonucleotides, DNA modified with drugs, 
hormones, chromatin or DNA in complexes with binding proteins (Stellar 1973; 1975, 
1986; Anderson et al, 1988a; Desai et al, 1993; Moinuddin and Ali, 1994; Hasan et al, 
1995; Theofilopoulous, 1995; Arjumand, et al, 1995; 1997; Arif and Ali, 1996). Reactive 
oxygen species modified DNA have been implicated in the pathogenesis of SLE and 
cancer (Ara and Ali, 1993; Du et al, 1994; Cooke et al, 1997; Ahmad et al, 1997). 
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Antibodies against 'O2-O2 -DNA were induced in rabbits by immunizing with 
'02-02^-DNA complexed with methylated bovine serum albumin. The '02-02~-DNA was 
a potent immunizing stimulus, inducing high titre antibodies. Specificity of purified 'O2-
02'-DNA IgG was assessed by competition ELISA. A maximum of 84.5% inhibition 
was observed with the immunogen. The concentration of immimogen required for 50% 
inhibition of IgG binding to immunogen was observed to be 1.9 fig/ml. In addition, the 
induced antibodies showed lesser binding to native DNA. The data indicates the higher 
specificity of the immune IgG towards ROS-modified epitopes. Modification of DNA by 
ROS might have generated potential epitopes against which the antibodies are raised. 
Native DNA, 200 bp DNA showed inhibitions of 47.8%, 32.3% respectively, whereas 
ROS-DNA showed higher inhibition of 50.25%. This indicates the increased recognition 
of free radical modified DNA by the induced anti-'02-02"-DNA antibodies. Chromatin 
and ROS-chromatin showed inhibition of 7,9% and 12.5% respectively. 
To further define the structural determinant recognized by the anti-'02-02'"-DNA 
antibodies, their interaction with various synthetic polynucleotides was studied. These 
compounds present a limited set of determinants than natural DNA and can be used as 
probe for specificity analysis. Poly(dA-dU).poly(dA-dU), poly(dI-dC).poly(dI-dC) and 
poly(dA-dT).po]y(dA-dT) showed an inhibition of 12.7%, 38.7% and 44.4% respectively. 
The broad recognition of the induced antibodies with a variety of polynucleotides might 
be due to the recognition of the phosphodiester backbone (Ballard and Voss, 1982; 
Shoenfeld et al, 1983; Ranch et al, 1985). Besides binding to various nucleic acids and 
synthetic polynucleotides, the anti-'02-02 -DNA IgG also showed cross reactivity 
towards chondroitin sulphate and cardiolipin. It has been suggested that phosphate sugar-
phosphate moiety of cardiolipin mimics the backbone of DNA, thus explaining the cross-
reactivity of immune IgG (Rauch et al, 1984). Analysis of the data indicates that anti-
'02-02~-DNA IgG is polyspecific and the various cross-reacting antigens with which it 
reacts shares a common antigenic determinant or epitope. 
SLE is a multisystem autoimmune disease involving both himioral and cellular 
aspects of the innate and acquired immune systems and is characterized by autoantibodies 
with a spectrum of specificities that participate in disease pathogenesis (Kimberly, 2001). 
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Sera of SLE patients contain a variety of autoantibodies of which a subset may be 
responsible for the array of chemical symptoms (Chastagner et al, 1994). Antibodies to 
dsDNA serve as a serological marker for the diagnosis of SLE. However, native DNA 
per se is non-immunogenic. It has been reported that denaturation of dsDNA by ROS 
results in an increased binding of anti-DNA antibodies present in sera of SLE patients 
(Blount, et al, 1989) and that ROS modification of DNA produces a more discriminating 
antigen for the diagnosis of SLE (Blount, 1990). The detection of 8-hydroxyguanosine in 
the immune complex derived DNA of SLE (Lunec et al, 1994) reinforces the evidence 
that ROS may be involved in SLE. Thus, it appears that ROS-modification exposes 
epitopes on DNA that are recognized by circulating anti-DNA antibodies in SLE sera. 
In the present study, anti-DNA antibodies from twenty four different SLE sera 
showed considerable binding to '02-02''-DNA except one sera which showed less 
binding to '02-02"-DNA than native DNA. No activity was found in normal human sera. 
When reactivity of native and '02-02'-DNA with SLE sera, was probed competition 
ELISA results showed preferential binding of '02-0'2~-DNA over native DNA. Band shift 
assay further substantiated the binding of native and '02-02"-DNA with SLE anti-DNA 
autoantibodies. The strong binding potential of anti-DNA IgG towards '02-02~-DNA 
demonstrates the possible role of modified nucleotides in SLE pathogenesis. 
Increased levels of circulating antibodies and autoantibodies have been reported 
in sera of patients with malignancies (Anderson et al, 1988b; Faiderbe et al, 1992; 
Chagnaud et al, 1992; Becker et al, 1994). Elevated levels of anti-nuclear antibodies up 
to 27% in cancer have been reported (Zeronski et al, 1972; Bunham, 1972). In the 
present study, serum of cancer patients were tested for the presence of autoantibodies 
reactive towards native and O2-O2 -DNA. In direct binding ELISA, almost all the cancer 
sera tested showed higher recognition of '02-02"-DNA by the circulating autoantibodies. 
The antigenic specificity of circulating antibodies analyzed by competition binding assay. 
Five sera fi-om lung cancer and three sera from oral carcinoma showed higher 
recognition for '02-0'2"-DNA as compared to native DNA. These patients have history of 
smoking and support for strong oxidative stress in vivo. It has been reported that lung and 
oral carcinomas are strongly correlated with oxidative DNA damage (Olinski et al, 1992; 
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Okamoto et al, 1994). Further, the binding to native and '02-02^-DNA with circulating 
cancer autoantibodies were substantiated by gel retardation assay. 
The results obtained with sera from cancer with urinary bladder, prostrate and 
Hodgkin's lymphoma have more preference for 'O2-O2-DNA as compared to nDNA 
thus suggesting the role of ROS damage to DNA in the development of these cancers. 
Patients suffering from breast cancer showed a higher reactivity towards 
02-02~-DNA than to its native analog. These results reiterate previous findings which 
suggest involvement of ROS damaged DNA in induction and progression of breast 
cancer (Jaiyesimi et al, 1992; Malins et al, 1993; 1996). Clinical significance of 
autoantibodies in cancer is unclear, however, the presence of anti-nuclear antibodies do 
indicate a worse prognosis or a more frequent recurrence of breast cancer (Tumbull et al. 
1978; Wasserman et al, 1975). 
The results obtained from sera of patients with gall bladder, head and neck, CML 
and vulva showed higher reactivity with 'O2-O2 -DNA as compared to its native analog. 
The data represented suggests that naturally occurring circulating autoantibodies in 
cancer patient have higher reactivity towards ROS modified DNA than towards native 
DNA. ROS appears to enhance antigenicity of native DNA, thus suggesting role of ROS 
damaged DNA in the production of autoantibodies in cancer patients. 
In the present study, attempts have been made to detect the oxidative lesions in 
DNA isolated from lymphocytes of various cancer patients by using anti- O2-O2 -DNA 
IgG as an immunochemical probe. 
DNA was isolated from lymphocytes of a group of six patients suffering from 
cancer of either lung, oral and prostrate. DNA from two patients with lung cancer 
recognized anti-'02-0"2~-DNA IgG appreciably and inhibited its activity to 64% and 68%. 
The results indicate presence of ROS induced lesions in DNA from patients with lung 
cancer. DNA from two patients with oral carcinoma too inhibited antibody activity 
appreciably. Prostrate cancer DNA exhibited 37% and 42.79% inhibition. All these 
resuhs indicate effective binding of anti-'02-02~-DNA IgG to DNA isolated from various 
cancer patients and confirms presence of ROS induced oxidative DNA lesions in cancer 
patients. 
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Based on this study, the following conclusions can be drawn: 
1. Illumination of DNA in presence of riboflavin resulted in structural alterations 
such as single strand breaks, disruption of hydrogen bonds and a consequent helix 
destabilization. 
2. Thermal transition studies showed that modified conformers are less stable as 
compared to native form. 
3. ROS induced certain conformational changes in DNA, rendering it highly 
immunogenic in experimental animals. 
4. The induced antibodies are highly specific for immunogen. 
5. The induced antibodies exhibited some cross-reactivity with various nucleic acids, 
synthetic polynucleotides thus resembling binding characteristics of SLE anti-
DNA antibodies. 
6. SLE anti-DNA autoantibodies showed preferential binding for '02-02~-DNA than 
nDNA. 
7. '02-02~-DNA presents a discriminating antigen for the binding of SLE 
autoantibodies. 
8. Antibodies in sera of various cancer patients were found to be more specific for 
'02-02~-DNA than for its native analog. 
9. Oxidative lesions were detected in DNA isolated from lymphocytes of cancer 
patients using anti- O2-O2 -DNA IgG as probe. 
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